compani report
initi under-perform single-asset pipelin carri
previous initi part outperform neutral
derm outperform acquir expand coverag univers
immunolog under-perform prvb outperform also initi
coverag outperform straddl therapeut area
skin diseas focu topic gene therapi platform illustr
pipeline-in-a-product approach could backfir heighten risk
high level confid lead indic lack prvb
provid histori teplizumab increment learn past
trial failur posit drug potenti chang landscap
type diabet examin first topic formul gene
therapi departur commonli use adeno-associ viral
aav vector hint mainstream diseas applic
underappreci risk head egid pivot trial
market cap singl drug antolimab valu higher
mani compani peer autoimmune/inflammatori space multi-
asset pipelin limit data singl phase placebo-control trial
eg/eg back antolimab believ investor gotten ahead
inadequ vet drug mechan given competitor
dupix fasenra compet deplet eosinophil eg/eg eoe
narr focus mast cell antolimab inhibitori effect look
underwhelm view risk around phase eg/eg trial skew
downsid blowup could take entir pipelin across indic
initi outperform topic gene therapi platform
innov hold potenti beyond diseas
stand apart gene therapi compani uniqu vector
use topic deliveri gene skin compani target
trio rare skin diseas deb arci netherton syndrom initi clinic
develop phase trial deb provid proof-of-concept
wound heal remark improv window compar placebo
manag hope take advantag acceler regulatori timelin
see readout phase deb trial file approv beyond
rare diseas gene therapi platform offer upsid facial aesthet treatment
common skin condit partner found out-licens
prvb initi outperform under-the-radar lead asset game-
changer type diabet
prvb pursu portfolio strategi build pipelin yield former mgnx/lli
asset teplizumab could chang treatment paradigm type diabet
initi shelv fail phase trial patient investigator-sponsor
studi later uncov teplizumab potent abil delay onset clinic
year averag at-risk pre-symptomat patient prvb seek approv
indic well potenti expand address popul
phase trial care select newli diagnos patient assum
regulatori file teplizumab could reach market prvb plan
target direct rel patient screen launch avail
nikko secur america inc nikko america affili seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor
make invest decis
initi under-perform single-asset pipelin carri
underappreci risk head egid pivot trial
pursu inflammatori diseas caus eosinophil mast cell target
antibodi antolimab compani entir pipelin predic antolimab
lead indic eosinophil gastrointestin diseas egid includ gastritis/gastroenter
eg/eg esophag eoe though mani investor left want detail data
phase enigma readout eg/eg manag sprint toward pivot trial howev sinc
compani commun fda feedback phase design timelin remain unconfirm
antolimab also assess chronic urticaria cu indol system mastocytosi ism
sever allerg conjunct sac trial declar posit despit subject endpoint lack
placebo control initi under-perform rate price target
plenti question remain phase forg ahead phase trial egid
preclin data suggest mechan level activ howev increment
contribut clinic efficaci steroid unclear without compar respons rate patient
receiv steroid concern statist signific enigma deriv hand
outlier mask current data sure come light larger phase trial care
scrutin fda correl eosinophil count subject symptom improv remain
unclear well role mast cell diseas biolog cusp start phase trial eg/eg
phase trial eoe also run new undisclos phase trial dose even though
initi mg/kg dose elimin eosinophil reduc symptom one two day
manag seek advanc dose high mg/kg phase unclear reason
despit evalu multipl indic commerci prospect antolimab look murki
regeneron/sanofi astrazeneca aim expand market biolog eg/eg eoe
gross price alreadi establish annual though eg/eg technic classifi rare
diseas expect allk price power cap competitor given two competitor
patient number simpli adequ sustain multi-billion-dollar opportun antolimab
price point sale cu ism sac could bolster antolimab franchis expect uptak
among limit number sever case wherea bulk patient default standard-of-car option
given lack placebo-control data produc far across cu ism sac also seem hesit
bring one indic next round clinic develop
multipl success price without downsid potenti failur mechan
trade high market cap back acquisit rumor decemb
make richli valu pre-revenu biotech compani world time although true
roch earli investor privat round think larg pharma due dilig would
remiss move forward without rigor conduct phase trial stock cut half
high base case scenario project addit downsid current level use risk-
adjust dcf valu allk single-asset pipelin ascrib antolimab valu egid cu
ism sac furthermor trial failur call question viabil
mechan would like sink remaind pipelin drive share trade cash valu
initi coverag
tabl content
debat investor
valuat market opportun
initi coverag under-perform
execut summari
clinical-stag biotechnolog compani develop therapeut antibodi inflammatori allerg diseas compani
found christoph bebbington nenad tomasev bruce bochner robert schleimer headquart redwood
citi ca juli complet ipo compani single-asset pipelin base antolimab
monoclon antibodi eosinophil gastrointestin diseas egid lead indic develop
egid includ eg/eg eoe gi tract affect chronic inflamm eosinophil mast cell phase
enigma trial evalu eg/eg well eoe subset report signific symptom improv almost complet
elimin eosinophil biopsi tissu manag push ahead phase trial eg/eg phase trial eoe
howev view narr incomplet sever key point includ correl symptom eosinophil count
potenti steroid confound result role mast cell diseas biolog upcom open-label extens data
enigma could increas confid go phase hand gap data could rais question answer
chronic urticaria cu inflammatori disord character hive itch either sporad respons stimulu
temperatur pressur evalu phase trial enrol sever urticaria sub-typ spontan cholinerg
dermatograph initi data suggest path forward xolair-refractori patient becom competit market segment
indol system mastocytosi ism inflammatori disord increas number activ mast cell throughout
bodi trigger symptom diarrhea abdomin pain sever itch caus cytokin releas aggress form
diseas consid blood cancer reduc life expect wherea lifespan affect indol version though
symptom debilit phase trial demonstr symptomat improv among ism patient
sever allerg conjunct sac describ broad rang allerg eye condit span season perenni allergi
sever vernal atop keratoconjunct milder form caus discomfort usual treat use anti-histamin mast cell
stabil soft topic steroid contrast sever variant requir potent steroid threaten vision swiftli
address phase trial show improv ocular sign symptom among sac patient
step cu ism sac remain unclear offici commit develop outsid egid also
express interest pivot diseas atop dermat mast cell gi diseas appear investor price success
one follow-on indic overlook risk yet-to-b valid mechan
valuat arriv per share price target under-perform rate
execut summari
tickerallkratingunderperformpric target price rang cap outstand total ep revenu
debat investor
initi coverag under-perform
debat investor
antolimab improv upon prior antibodi termin
phase studi allk day privat compani
first antibodi advanc
clinic develop evalu phase trial nasal
polyp turnov manag current leadership
team termin nasal polyp studi
benefit seen primari endpoint chang
baselin total polyp score tp week treatment
dose background nasal steroid studi
appear underpow statist comparison
phase trial
subject
chang tp wk
phase trial outcom nasal polyp
accord one allk founder dr bruce bochner human non-fucosyl antibodi contrast
appear fucosyl antibodi
specif target therefor abl induc apoptosi eosinophil
inhibit mast cell activation/degranul similar degre target engag
remov sugar residu fucos improv bind fc portion fcriii nk cell nk cell bind
contrast abl kill eosinophil activ
via apoptosi well inact state via adcc
recent paper legrand et al allergi clin immunol demonstr
eosinophil-kil abil similar presenc
activ ligand kill eosinophil absenc
theori also induc adcc mast cell
reduct peripher tissu mast cell count anoth biomark
clinic efficaci addit peripher tissu eosinophil count
serum tryptas histor consid specif marker mast
cell activ must measur within hr episod compar
baselin better correl larg bulk mast cell mastocytosi
could miss smaller number pathogen mast cell locat tissu
compani report compani file compani press releas compani websit legrand et al allergi clin immunol akin jaci bruce bochner lectur institut biolog
debat investor
correl deplet eosinophil symptom improv eg/eg eoe
deliv fastest known eo deplet
agent
common wisdom symptom improv requir
chronic inflamm resolv week
investig date
phase studi everi dose wipe
eo undetect level hour post-dos
dose elimin eo month
advanc phase mg/kg
phase studi everi eg/eg patient
start mg/kg later escal
mg/kg low dose mg/kg high dose
within day receiv start dose
mg/kg patient experienc
major symptom improv
hypothes eosinophil deplet
quickli reflect endoscopy/histolog
eoe symptom take longer improv
demonstr earliest respons
eoe start week treatment
phase studi volunt
phase enigma studi eg/eg patient
debat investor
could steroid use confound efficaci result phase engima studi eg/eg
enigma steroid use permit set chronic daili
use pre-dos prior infus post-dos manag irr
latter set compris acut use appear
investig discret high steroid dose prednison mg solu-
medrol mg would need control irr first visit
wide use steroid
remain mainstay induc
remiss eg/eg
howev know medic literatur steroid rapidli
improv patient symptom eg/eg also deplet eosinophil
combo kill tissu sequestr albeit transient
phase data provid make challeng discern
steroid may contribut report symptom improv
arm predispos higher rate irr
requir higher steroid dose potenti unblind patient
induc eosinophil apoptosi
initi respons rate
report literatur
dose mg/kg
dose typic taper
steroid higher affin
steroid receptor
lower system impact
dose mg/day
taper mg/day
better safeti profil lend
chronic usag diseas
takeda file approv
budesonid eoe
data
provid
term
rate
better
steroid
similar acut steroid use report across
group inform given
cumul dose frequenc dose
subgroup analysi includ steroid group report unusu manner use p-valu
typic one would show respons rate denot statist signific p-valu footnot
visual actual delta respons rate drug placebo group
debat investor
mast cell fit patholog eosinophil gastrointestin diseas egid known
effect antolimab mast cell
earli studi target mast cell antibodi
fail induc apoptosi prevent degranul
releas histamin prostaglandin
develop non-fucosyl fc region
allow adcc mast cell reduc mast cell count
preclin mous model eg/eg
reduct eo compar robust sinc apoptosi
caus binding/crosslink addit adcc
screen enigma studi symptomat
patient elev mast cell count /-eo mani
screen due meet criteria eosinophilia
manag plan new phase studi popul
better understand impact pure mast cell inhibition/deplet
infiltr
evalu mous model eg/eg gi
eosinophil mast cell could stimul addit protein ova
singl dose mab reduc eo back unstimul level
day much modest effect mast cell
end phase enigma studi low mg/kg
high mg/kg dose almost fulli deplet
tissu eosinophil reduct baselin
contrast tissu mast cell modestli reduc baselin across gi
tract region similar preclin data duoden biopsi show statist
signific mast cell reduct mast cell count broken low vs high dose
debat investor
expect phase enigma open-label extens data eg/eg find would
increas confid upcom phase trial
understand long-term symptom improv trend seen
expect co-primari endpoint phase
mean chang tissu
eo baselin
understand long-term tissu eo deplet seen
expect co-primari endpoint phase like
cutoff valu eos/hpf
eoe eref use quantifi diseas activ
eg/eg non-specif find includ mucos
hyperemia thicken gastric fold loss villi
mean chang blood
eo baselin
correl tissu eo given phase data show
massiv sustain reduct one dose
mean chang tissu
mast cell baselin
mechan preclin data indic mast cell
moder deplet
mean chang blood
mast cell baselin
correl tissu mast cell
biomark mast cell
tryptas histamin best indic mast cell
inhibit mechan result inhibit
protocol phase dose trial one clinic site
open-label extens studi expect provid
addit month patient data start mg/kg
dose mg/kg monthli
lack placebo control arm comparison tabl
right list endpoint extens studi
addit data could provid greater confid
head pivot phase trial
blood/tissu eo blood/tissu mast cell mast cell
activ data double-blind portion trial
data never publicli releas fda
sure access
meet
moreov endpoint becom focu phase
scrutin fda review process
result
also run new phase dose trial
determin go-forward dose phase
mg/kg expect tissu eo deplet new
studi contempl much higher dose mg/kg
predos regimen appear codifi
prednison mg prior first dose
acetaminophen anti-histamin prior everi dose
iv infus window estim hour appear
slight improv enigma hour
routin case ran longer hour
extens studi infus
patient hour longer time new phase studi
like precautionari irr mg/kg dose
fda food drug administr irr infusion-rel reaction irb institut review board
debat investor
fda expect endpoint upcom trial antolimab eg/eg eoe
design pivot studi
hold meet fda expect start phase eg/eg trial phase eoe trial think
prior trial eg/eg eoe provid roadmap fda requir approv endpoint
eoe co-primari endpoint like includ one measur histolog one measur symptom improv
appear fda allow histolog eosinophil count biopsi tissu eos/hpf primari endpoint request endoscopi
secondari endpoint diverg two measur could view red flag
dsq appear prefer tool eoe seem easiest path would adopt dsq vs new proprietari tool
eg/eg expect fda adopt similar stanc requir co-primari endpoint histolog symptom improv
think fda could concern allk proprietari eg/ege-pro symptom score given vomit includ yet patient
phase enigma studi exhibit meaning vomit baselin treatment tool may requir valid prior phase
absolut chang straumann
score baselin wk
patient achiev peak
eos/hpf baselin wk
patient achiev histolog
respons peak eo count
eos/hpf baselin wk
induct diseas remiss peak
eo count baselin
absolut chang dysphagia
baselin wk
patient achiev symptom
respons reduct dsq
baselin wk
chang overal peak esophag
intraepitheli eos/hpf baselin wk
absolut chang eoe-endoscop
baselin wk
absolut chang eoe endoscop
refer score eref baselin
absolut chang eoe grade score
eoehss baselin wk
co-primari secondari endpoint
baselin wk
chang total endoscopi score
baselin wk
chang peak eo count baselin
wk
chang histopatholog epitheli
featur baselin wk
chang endoscop featur
peak eo count biopsi gi
symptom qualiti life eoe-
qualiti life scale
treatment baselin year
debat investor
extent futur commerci prospect antolimab limit current market biolog
expand indic
eg/eg classifi rare diseas patient eoe borderlin rare patient label expans current
market biolog indic would place cap upper limit price
given current price dupix fasenra antibodi think new entri eg/eg
eoe would cap annual list price gross price assum discount primarili rebat
manag care favor formulari tier placement restrict access arriv net price
approv mix rare common diseas could possibl given mast cell eosinophil implic wide varieti
autoimmune/inflammatori condit howev price power rare diseas limit lower price common diseas unless
differ brands/formul market differ price indication-bas price arrang
would high bar safety/toler given risk-benefit profil current market biolog well known
work subcutan formul first data expect view success inject version
absolut necess remain competit
use asthma biolog market proxi find teva cinqair sole iv-administ agent inconveni
infus drug multipl inject avail sever handicap market opportun cinqair see fy net sale
iv formul non-start multi-hour infus time plu steroid pre-dos need prevent infus reaction initi
visit even cut infus time hour add limit valu compet inject substitut see cinqair
gi practic appear ill-equip infus would need hire addit nurs support send patient infus center
manufactur rout admin
load dose
first dose
averag cost highli variabl sinc dose asthma base patient level ige
eg eosinophil gastriti ege eosinophil gastroenter eoe eosinophil esophag il interleukin iv intraven ad atop dermat crswnp chronic rhinosinus nasal pulp egpa
eosinophil granulomatosi polyangi cu chronic urticaria qxw everi week
debat investor
priorit pipelin eosinophil mast cell diseas beyond eg/eg eoe
effort focus advanc develop eg/eg eoe beyond also conduct phase
proof-of-concept studi cu ism sac potenti indic label expans
howev difficult identifi studi demonstr efficaci merit addit invest develop
studi enrol small sampl size util subject scale measur efficaci open-label placebo arm
studi cu sac enrol heterogen popul differ diseas subtyp creat hurdl uniform
patient select larger trial
view none indic provid particularli compel rational commerci and/or regulatori perspect
indic fairli competit multipl standard-of-car option least one major competitor along develop
dermatograph urticaria
address popul sizabl model
patient inadequ control xolair
biolog rational sound mast cell accept
primari effector diseas
high-profil competitor investor attent direct
advanc form mastocytosi
novarti evalu ligelizumab phase studi
plan replac xolair new molecul ligelizumab
like domin new patient need
switch xolair
enrol patient new studi difficult given
size ligelizumab trial combin
other could quickli pivot/expand program
aggress indol form
includ pac akc vkc
could address
without kit mutat target bpmc avapritinib
doc may see better valu proposit drug
treat full spectrum indol advanc diseas
necessit improv one symptom one sign
endpoint allerg conjunct
sever form akc vkc limit treatment
option therapi develop
even approv unlik gain traction broader pac
popul accustom prefer topic
payer histori restrict manag eye
care categori given abund anti-histamin
steroid option standard-of-car
valuat market opportun
initi coverag under-perform
arriv price target base risk-adjust discount cash flow dcf model assum
weight averag cost capit wacc termin growth rate share outstand million
valu antolimab eosinophil gastrointestin diseas egid chronic urticaria cu indol system mastocytosi
ism sever allerg conjunct sac
present includ autoimmune/inflammatori diseas mast cell eosinophil may play role
atop dermat asthma mast cell gastrointestin diseas valuat indic repres upsid current estim
dcf discount cash flow wacc weight averag cost capit egid eosinophil gastrointestin diseas cu chronic urticaria ism indol system mastocytosi sac sever allerg
valuat assumpt
valuat assumpt
 eu market entri egid
eg-eg eoe
 eu peak sale million
risk-adjust discount blend
eg-eg eoe
extens data phase enigma trial
confid phase
outcom reduc risk-adjust
egid discount blend
eg-eg eoe
extens data enigma trial
egid decreas confid phase
outcom and/or neg feedback fda
meet remov egid
valuat adjust oper expens
 eu market entri cu csu
urticaria eu peak sale
 million risk-adjust
 eu market entri ism
 eu peak sale
million risk-adjust discount
 eu market entri sac pac
akc vkc eu peak
sale million risk-adjust
addit data phase trial
cu
increas confid phase outcom
cu
sub-typ discount
advanc clinic develop
cu due pipelin priorit
remov cu valuat adjust
addit data phase trial
ism
increas confid phase outcom
ism
advanc clinic develop
ism due pipelin priorit
remov ism valuat
addit data phase trial
sac
increas confid phase outcom
reduc risk-adjust sac
subtyp discount
advanc clinic develop
sac due pipelin priorit
remov ism valuat
increas confid mechan
trial reduc
across clinic
adjust individu note
decreas confid mechan
across clinic trial model adjust
individu note
failur on-going and/or plan clinic trial antolimab eg/eg eoe cu ism and/or sac may
impact estim target price and/or rate decis priorit de-priorit clinic develop
indic may also lead revis estim target price and/or rate given allk pipelin rest
singl asset yet approv indic heighten risk rel similar compani
diversifi pipelin assets/mechan clinic trial failur indic call question mechan
could decreas confid on-going and/or futur trial diseas share similar underli biolog
fda ema and/or ex-u regulatori agenc may delay and/or deni approv eg/eg eoe cu ism
and/or sac fda align phase trial design eg/eg and/or phase trial design eoe initi
studi may postpon given period time indefinit fda satisfi qualiti and/or quantiti
data produc eg/eg and/or eoe trial rel competitor product agenc may requir new trial
conduct specif addit trial push back expect develop timelin
loss first-mover/competit advantag and/or commercial/govern reimburs eg/eg eoe cu ism
and/or sac may impact estim target price and/or rate expect seek commerci asset
approv hiring/deploy salesforc except partner think feasibl effect
launch eg/eg eoe eu without partner given rel small size address
popul concentr prescrib base price power may limit current market product seek
obtain label expans eg/eg eoe and/or biolog
competitor product approv market prior allk and/or competitor superior
therapeut profil could advers impact eg/eg eoe compet investig product
regn/san-fr dupix azn fasenra gsk nucala tak budesonid oral suspens adar
cu compet investig product novn-ch ligelizumab well market
product rog-ch/novn-ch xolair ism compet investig product avapritinib
ab-fr masitinib well soc therapi anti-histamin steroid
sac compet
investig product dextenza aktx nomacopan well soc therapi mast cell stabil anti-
histamin steroid
depend cash flow statu probabl success develop eg/eg eoe cu ism and/or
sac compani may need rais addit fund financ sg activ come year model
next equiti rais
aktx akari therapeut soc standard-of-car il interleukin fda food drug administr ema european medicin agenc
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
eosinophil gastriti eg popul age y-o-i growth patient eosinophil gastriti eg patient eg fail first-lin treatment predisone/c popul patient treat market growth annual price/rx price annual revenu eosinophil gastriti eg growth gastriti eg popul age y-o-i growth patient eosinophil gastriti eg eu patient eg fail first-lin treatment prednisone/c eu popul patient treat market growth annual revenu eosinophil gastriti eg eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
eosinophil gastroenter ege popul age y-o-i growth patient eosinophil gastroenter ege patient ege fail first-lin treatment prednisone/c popul patient treat market growth annual price/rx price annual revenu eosinophil gastroenter ege growth gastroenter ege popul age y-o-i growth patient eosinophil gastroenter ege eu patient ege fail first-lin treatment prednisone/c eu popul patient treat market growth annual revenu eosinophil gastroenter ege eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
eosinophil esophag eoe popul age y-o-i growth patient eosinophil esophag eoe patient eoe fail first-lin treatment ppi popul patient eoe fail second-lin treatment topic cs popul eoe fail first-lin treatment patient treat market growth annual price/rx price annual revenu eosinophil esophag eoe growth esophag eoe popul age y-o-i growth patient eosinophil esophag eoe eu patient eoe fail first-lin treatment ppi eu popul patient eoe fail second-lin treatment cs eu popul eoe fail first-lin treatment patient treat market growth annual revenu eosinophil esophag eoe eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
chronic spontan urticaria popul age y-o-i growth popul adult year old adult patient chronic spontan urticaria csu popul adult year adult patient csu fail first-lin treatment anti-histamin adult patient adult patient csu fail second-lin treatment xolair adult patient csu fail first-lin treatment adult patient treat market growth annual price/rx price annual revenu chronic spontan urticaria growth spontan urticaria popul age y-o-i growth popul adult year old eu adult patient chronic spontan urticaria csu eu popul adult year adult patient csu fail first-lin treatment anti-histamin adult patient adult patient csu fail second-lin treatment xolair adult patient csu fail first-lin treatment adult patient treat market growth annual revenu chronic spontan urticaria eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
cholinerg urticaria popul age y-o-i growth popul adult year old adult patient cholinerg urticaria popul adult year adult patient cholinerg urticaria fail first-lin treatment anti-histamin adult patient cholinerg adult patient cholinerg urticaria fail second-lin treatment xolair adult patient cholinerg urticaria fail first-lin treatment adult patient treat market growth annual price/rx price annual revenu cholinerg urticaria growth urticaria popul age y-o-i growth popul adult year old eu adult patient cholinerg urticaria eu popul adult year adult patient cholinerg urticaria fail first-lin treatment anti-histamin adult patient cholinerg adult patient cholinerg urticaria fail second-lin treatment xolair adult patient cholinerg urticaria fail first-lin treatment adult patient treat market growth annual revenu cholinerg urticaria eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
dermatograph urticaria popul age y-o-i growth popul adult year old adult patient dermatograph urticaria popul adult year adult patient symptomat dermatograph adult patient dermatograph adult patient symptomat dermatograph fail first-lin treatment anti-histamin adult patient symptomat adult patient symptomat dermatograph fail second-lin treatment xolair adult patient symptomat dermatograph fail first-lin treatment adult patient treat market growth annual price/rx price annual revenu dermatograph urticaria growth urticaria popul age y-o-i growth popul adult year old eu adult patient dermatograph urticaria eu popul adult year adult patient symptomat dermatograph adult patient dermatograph adult patient symptomat dermatograph fail first-lin treatment anti-histamin adult patient symptomat adult patient symptomat dermatograph fail second-lin treatment xolair adult patient symptomat dermatograph fail first-lin treatment adult patient treat market growth annual revenu dermatograph urticaria eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
indol system mastocytosi popul age y-o-i growth popul adult year old patient indol system mastocytosi popul adult year adult ism patient symptom inadequ control soc treatment adult patient patient treat market growth annual price/rx price annual revenu indol system mastocytosi growth system mastocytosi popul age y-o-i growth popul adult year old eu patient indol system mastocytosi eu popul adult year adult ism patient symptom inadequ control soc treatment adult patient adult patient treat market growth annual revenu indol system mastocytosi eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
perenni allerg conjunct popul age y-o-i growth popul adult year old adult patient perenni allerg conjunct pac popul adult year adult patient pac seek treatment/not respond over-the-counter med adult patient adult patient pac fail first-lin treatment mast cell stabil anti-histamin adult patient pac seek adult patient pac fail second-lin treatment topic cs cni adult patient pac fail first-lin treatment mast cell stabil adult patient treat market growth annual price/rx price annual revenu perenni allerg conjunct growth allerg conjunct popul age y-o-i growth popul adult year old eu adult patient perenni allerg conjunct pac eu popul adult year adult patient pac seek treatment/not respond over-the-counter med adult patient adult patient pac fail first-lin treatment mast cell stabil anti-histamin adult patient pac seek adult patient pac fail second-lin treatment topic cs cni adult patient pac fail first-lin treatment mast cell stabil adult patient treat market growth annual revenu perenni allerg conjunct eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
atop keratoconjunct popul age y-o-i growth popul adult year old adult patient atop keratoconjunct akc popul adult year adult patient akc fail first-lin treatment mast cell stabil anti-histamin adult patient adult patient akc fail second-lin treatment topic cs cni adult patient akc fail first-lin treatment mast cell stabil adult patient treat market growth annual price/rx price annual revenu atop keratoconjunct growth keratoconjunct popul age y-o-i growth popul adult year old eu adult patient atop keratoconjunct akc eu popul adult year adult patient akc fail first-lin treatment mast cell stabil anti-histamin adult patient adult patient akc fail second-lin treatment topic cs cni adult patient akc fail first-lin treatment mast cell stabil adult patient treat market growth annual revenu atop keratoconjunct eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
vernal keratoconjunct popul age y-o-i growth popul adult year old adult patient vernal keratoconjunct vkc popul adult year adult patient vkc fail first-lin treatment mast cell stabil anti-histamin adult patient adult patient vkc fail second-lin treatment topic cs cni adult patient vkc fail first-lin treatment mast cell stabil adult patient treat market growth annual price/rx price annual revenu vernal keratoconjunct growth keratoconjunct popul age y-o-i growth popul adult year old eu adult patient vernal keratoconjunct vkc eu popul adult year adult patient vkc fail first-lin treatment mast cell stabil anti-histamin adult patient adult patient vkc fail second-lin treatment topic cs cni adult patient vkc fail first-lin treatment mast cell stabil adult patient treat market growth annual revenu vernal keratoconjunct eu growth
initi coverag under-perform
manag
dr alexand involv format leadership numer biotechnolog compani dr alexand ceo zs pharma
led initi public offer sale zs pharma astrazeneca prior zs pharma dr alexand director alta partner
ventur capit firm also execut chairman interim ceo sarcod bioscienc time alta partner led
invest sarcod bioscienc acquir shire acquir shire zs pharma acquir astrazeneca
prior alta partner dr alexand princip mpm capit bioequiti fund robert join mpm genentech
work busi develop group
dr alexand board director hold phd univers north carolina chapel hill
bachelor scienc zoolog miami univers ohio
presid chief oper offic
prior join dr tomasi chief scientif offic head corpor develop zs pharma led scientif
busi develop investor relat function compani initi public offer sale astrazeneca join zs
pharma dr tomasi princip alta partner contribut invest zs pharma acquir astrazeneca lumena
acquir shire excaliard acquir chemgenex acquir cephalon achaogen immun design
dr tomasi serv drug discoveri scientist
dr tomasi hold bachelor scienc chemistri univers california berkeley mit phd chemistri
univers california irvin
dr rasmussen year experi pharmaceut biotech industri prior join dr rasmussen
zs pharma work prior join zs pharma presid ceo rasmussen
 pharma consult dr rasmussen held posit corpor vice presid head clinic develop medic
regulatori affair novo nordisk genvec senior vice presid clinic
research regulatori affair british global studi director cardiovascular drug develop pfizer central research
dr rasmussen led numer global develop program regulatori file world-wide includ ind clinic trial applic
nda supplement new drug applic snda biolog licens applic bla mma file publish
peer-review paper therapeut area nephrolog cardiolog ophthalmolog gastroenterolog diabet
dr rasmussen receiv md phd univers copenhagen denmark train intern medicin cardiolog
mr redmond join august chief offic close three decad experi biopharmaceut
industri prior join mr redmond serv chief offic secretari presidio pharmaceut clinical-stag
pharmaceut compani serv presid cfo secretari presidio mr redmond also
serv member board director presidio sinc mr redmond work genentech
senior director financ mr redmond also serv cfo secretari
genentech foundat biomed scienc prior join genentech mr redmond work gte corpor variou financi
mr redmond bachelor scienc doubl major busi administr account univers kansa
mba ucla anderson school manag
manag
mr asburi join novemb chief legal offic gener counsel year pharmaceut
industri variou size compani sinc mr asburi gener counsel samsara biocapit science-driven ventur capit firm
mr asburi chief legal offic gener counsel zs pharma acquir astrazeneca
respons legal aspect organ includ intellectu properti sec matter strateg transact prior zs pharma
vice presid gener counsel pharmacycl help compani negoti million deal johnson
johnson ibrutinib phase molecul prior mr asburi held varieti posit genentech recent associ
gener counsel senior director transact law prior join genentech work law firm shearman sterl
special corpor financ merger acquisit commerci debt financ
mr asburi ba soviet studi vanderbilt univers jd stanford law school
dr greenwood year experi healthcar industri prior join dr greenwood invest director
roch ventur fund led invest biodesi cytomx cymx dv acquir epic
scienc horizon discoveri aim hzd maculogix proacta strato prior role roch ventur fund dr greenwood
head genenfund genentech corpor ventur fund also held role research busi develop genentech
dr greenwood hold phd genet develop columbia univers colleg physician surgeon
mr varacek year experi biopharmaceut sale account manag market commerci oper leadership
recent mr varacek senior vice presid sale commerci oper zs pharma acquir astrazeneca prior
zs pharma held varieti execut management-level role intermun acquir roch ag affymax bm
commerci leadership role mr varacek launch expertis specialti non-specialti orphan diseas product includ biolog
small molecul compound
mr varacek bachelor scienc biolog suni binghamton
receiv feedback fda meet phase trial design
initi pivot phase trial eg/eg
top-line data phase open-label extens trial eg and/or ege
initi phase trial eoe
top-line data phase trial mast cell gi disord
top-line data phase trial sc formul healthi volunt
cu ism sac
commun next step plan clinic develop
file approv eoe base posit pivot phase orbit trial result
top-line data pivot phase trial eoe
top-line data investigator-sponsor phase trial eoe
top-line data investigator-sponsor phase trial eg/eg
top-line data pivot phase trial eoe
top-line data investigator-sponsor phase trial eg/eg
top-line data phase trial csu
initi top-line data phase translat trial csu
top-line data phase trial ism/ssm
top-line data confirmatori phase trial ism
top-line data confirmatori phase trial pac
top-line data phase proof-of-concept trial moderate-to-sever akc
initi coverag under-perform
understand biolog
logic target dampen immun function eosinophil mast cell though interact receptor
broad rang endogen ligand well understood
inhibitori receptor belong superfamili siglec
found abundantli surfac matur eosinophil present lesser degre mast cell basophil
activ cell myeloid progenitor also report express
endogen sialoglycan mani remain uncharacter ligand found mammalian cell
natur purpos halt contain inflammatori respons immun cell includ eosinophil mast cell
contain intracellular itim itsm domain
upon engag ligand domain trigger downstream signal ultim result immun cell death inhibit
although two isoform differ intracellular domain share common extracellular receptor domain
target antibodi
gener schemat inhibitori receptor signal applic
paul et al natur review shik et al clinic experiment allergi osullivan et al frontier medicin
sialoglycan ligand recogn siglec-f mous paralog
antibodi understand mechan action
antibodi bind differenti effect eosinophil cell death mast cell inhibit though antibodi
modifi induc death cell type second mechan
crosslink antibodi mediat cell death
mani inhibitori receptor exist surfac mast cell
eosinophil apoptosi
includ fcgriib pir-b siglec
cell death prime cell stimul
gener ro
death less pronounc mainli caspase-depend
antibodi fc region may also bind nk cell
eosinophil-kil effect crosslink
enhanc presenc gm-csf
prevent degranul inflammatori mediat
antibodi bind mast cell trigger
apoptosi eosinophil cell deplet could achiev
simultan bind nk cell induc
bind eosinophil univers signal apoptosi lead
cell death eosinophil may also kill adcc
antibodi capabl engag nk cell
bind mast cell result inhibit degranul
secretori respons rather cell death mast cell could still kill
adcc antibodi capabl engag nk cell
predecessor antolimab
predecessor demonstr similar eosinophil-kil abil preclin studi
condit fail translat clinic efficaci nasal polyp trial
background
variabl bind region
fucosyl fc region limit bind
nk cell nk-cell mediat adcc
vitro efficaci similar eosinophil
deplet presenc wherea exhibit limit
cell-kil abil absenc
theori eosinophil diseas character high
level henc efficaci market antibodi
azn fasenra gsk nucala teva cinqair
nasal polyp
textbook case eosinophil diseas
random double-blind placebo-control studi
enrol patient moderate-to-sever chronic nasal
polyposi symptom resist treatment intranas steroid
iv inject mg placebo day
primari endpoint chang total polyp score tp
nasal polyp trial deem underpow
endpoint comparison manag termin earli
treatment either mg mg fail differ
placebo observ dose-respons relationship
decid pursu develop
similar eosinophil kill demonstr
phase trial
subject
chang tp wk
phase trial outcom nasal polyp
initi began develop two product candid
monoclon antibodi target siglec-
compound enter clinic develop
respect due greater activ decid focu
develop effort discontinu develop
current plan continu develop
may choos futur
allako manag amend file
improv upon predecessor fucos residu strip fc region permit adcc-
mediat kill eosinophil wider rang condit
chimer antibodi target develop murin variabl region human constant region known
antibodi share variabl bind region exhibit similar select bind efficaci
differenti afucosyl fc region enhanc bind fcriiib nk cell allow
profound adcc
engag may potenti trigger cytokin releas nk cell neutrophil non-specif way could
contribut infus reaction system toxic
induc kill activ
eosinophil prime similar degre kill measur
apoptot fraction annexin eo
kill non-activ eosinophil absenc
provid nk cell ad solut allow adcc
effect eosinophil prime
demonstr rapid reduct eosinophil mast cell mous model eg/eg potent effect
deplet eosinophil rel mast cell
direct evid efficaci lack anim model
egid diseas model establish intragastr challeng
due differ gene express human mice
ovalbumin ova
close function paralog mice siglec-f
howev mast cell mice express siglec-f
mab expect effect
siglec-f induc intern receptor
stimul ova lead elev eosinophil mast cell
level mous stomach/intestin similar human eg/eg
inflamm accompani increas cytokin
treatment mab suppress diseas activ
transgen mous model
therefor develop
return eosinophil mast cell count blood stomach
demonstr proof-of-concept use murin version
intestin mln back almost normal level
murin mab engin base
reduc express type immuneassoci inflammatori
mediat adcc mice similarli human
cytokin chemokin intestin tissu serum
transgen mice engin express receptor
eosinophil mast cell
interestingli eosinophil reduct mice less near
complet deplet later wit human studi
gi
tissu
mice eg/eg
ova-induc
signific reduct eosinophil mast
cell gi tissu mice eg/eg within
day administr antibodi dose day
cell measur day
administr mab reduc
eosinophil gi tissu mice eg/eg
transgen model ova-induc eg/eg
antolimab phase trial volunt
drug usual perform better preclin studi optim condit lab surprisingli
outperform human eosinophil deplet vs maximum vitro
random double-blind placebo-control dose-escal
phase data healthi volunt show superior
eosinophil deplet compar preclin studi
iv infus
absolut peripher blood count
half-lif day mg/kg dose cohort
dose complet deplet eosinophil hour infus
dose-respons relationship observ increas durat
complet eosinophil deplet higher dose
assum averag weight kg blood volum
tissu distribut process peak concentr lowest
dose cohort mg/kg like g/ml
vitro data obtain allk patent file indic dose
g/ml low-fucos chimer result
eosinophil deplet peripher blood sampl taken
healthi volunt incub hour
data presum incorpor benefit nk-mediat
adcc eosinophil kill sinc chimer
variant retain fucos residu fc region
total allk vitro vivo data suggest
eosinophil deplet depend experiment condit
vitro data
deplet
hour
hour
phase studi volunt
vitro data peripher blood leukocyt
antolimab phase engima trial eg/eg
phase engima trial eg/eg first placebo-control trial enrol patient skew toward
milder eosinophilia allow liber use steroid protocol
enrol patient age year old
diagnos eg/eg confirm biopsi
chang tissu eosinophil per hpf
gastric
and/or duoden biopsi day
chang eg and/or ege symptom
questionnair develop day
steroid consid part standard-of-car
therapi egid protocol permit steroid use
follow condit
daili oral prednison must
screen start stabl
throughout screen baselin studi period
protocol violat consid increas
decreas daili steroid amount
acut steroid use premed infus
therapeut manag irr
patient baselin demograph rel
patient skew toward milder popul
report blood eosinophil per
major enigma patient exhibit mild eosinophilia cells/l
antolimab enigma result efficaci eosinophil
robustli deplet tissu eosinophil vs surpris increas among placebo-tr patient despit steroid use
remain uncorrobor blood eosinophil count
recal dose administ
activ treatment arm follow dose
schedul day
tissu eosinophil count almost complet
deplet reduct either low dose
mg/kg high dose
mg/kg
placebo-tr patient saw increas
steroid usag pre- post-dos prednison
mg compar patient
patient receiv acut steroid
placebo arm among per protocol group
increas
would
acut
phase enigma efficaci eosinophil reduct baselin
eosinophil apoptosi sequestr
manag attribut mild tissu eosinophil
increas among placebo-tr patient random
chanc small sampl size
patient eos/hpf
eos/hpf contrast none patient
placebo arm met cutoff eos/hpf
blood eosinophil count provid
blood eosinophil correl tissu
eosinophil given blood eosinophil
deplet much lower dose mg/kg
phase trial healthi volunt
phase enigma efficaci eosinophil
antolimab enigma result efficaci mast cell
modestli reduc tissu mast cell post-treat level still fall within patholog rang
duoden biopsi show signific reduct compar placebo
contrast eosinophil deplet inhibitori effect mast cell
appear mediocr modest reduct mast cell count post-
treatment across biopsi region
signific differ mast cell reduct observ
placebo except duoden biopsi
p-valu report suggest could borderlin compar
massiv eosinophil reduct low- high-dos
though numer decreas mast cell level post-treat remain
within patholog rang far normal level
previou studi averag level mast cell among eg/eg patient found
per hpf across gastric duoden biopsi similar post-
treatment level
mechan suggest challeng kill tissu mast cell
mast cell kill reliant adcc requir nk cell
less like found traffick tissu
mast cell
per hpf averag
treatment
miss
end studi
unclear
larg dispar
biopsi baselin
end phase enigma studi low mg/kg
high mg/kg dose almost fulli deplet
tissu eosinophil reduct baselin
contrast tissu mast cell modestli reduc baselin across gi
tract region similar preclin data duoden biopsi show statist
signific mast cell reduct mast cell count broken low vs high dose
antolimab enigma result efficaci symptom
develop questionnair assess eg/eg symptom suggest preval vomit
popul vs patient actual enrol
questionnair eg/ege-sq measur symptom improv
accord fda guidanc
total interview conduct eg/eg patient
sign symptom report
final questionnair pare eight symptom
includ frequent report abdomin pain
nausea diarrhea vomit
enigma trial improv symptom sever
symptom symptom record
everi symptom except vomit
bizarr none
patient receiv exhibit
vomit baselin treatment
rais question patient enrol
vomit thought
defin symptom eg/eg
experienc patient develop
altern vomit appear predict valu
inclus questionnair seem superflu
data provid patient composit
understand dose respons individu symptom
individu symptom basi data provid placebo-
individu symptom basi data provid patient
receiv steroid vs steroid
develop
high rate vomit
vomit baselin post-
treatment enigma studi
antolimab enigma result efficaci symptom
treatment deliv symptom improv reduct eosinophil yet receiv placebo led
symptom improv increas eosinophil
present outcom chang baselin total
symptom score tss dose significantli
improv tss compar placebo
improv baselin measur tss
given acut steroid use dose prednison mg
unlik pure placebo effect
placebo-adjust symptom improv combin
low-dos high-dos
given symptom appear score scale
baselin symptom symptom
placebo-adjust improv would equat score
treatment
placebo-tr patient saw symptom improv
averag despit increas baselin eosinophil
suggest complex relationship eosinophil count
symptom improv unlik linear
treatment
respond classifi patient achiev
reduct tissu eosinophil count reduct
unclear cutoff select whether
fda like appli stress test respond analysi
determin robust
select cutoff whether
select slightli differ cutoff dramat chang number
respond vs non-respond
antolimab enigma result efficaci symptom
patient experienc symptom improv first dose also would
like receiv acut steroid manag irr
improv symptom begin first day
infus
major
improv achiev within first day
given patient irr
irr cluster around first dose would expect
higher acut steroid use arm around
time symptom improv
use prior studi proxi celg
improv take week occur first dose
eosinophil deplet addit time requir
tissu damag gi tract revers
minim
improv
symptom
first day treatment
seem odd manag desir take
mg/kg even mg/kg phase trial
mg/kg appear deliv
benefit observ phase trial
respond analysi select
reduct tissu eosinophil count
reduct symptom tss cutoff
placebo arm week
look
appar averag symptom improv
exce tss cutoff respond
placebo arm also happen deterior
primari endpoint week
improv delta
two arm
hypothes eosinophil deplet
quickli reflect endoscopy/histolog
eoe symptom take longer improv
demonstr earliest respons
eoe start week treatment
major
phase enigma studi eg/eg patient
antolimab enigma result efficaci symptom
sensit analysi rais question answer highlight larg deterior symptom improv
arm exclud patient ad back analysi
provid sensit analysi stratifi patient steroid use report result
intent-to-treat vs per protocol pp popul
analysi random alway analyz provid rigor conserv
estim treatment effect
pp analysi exclud protocol violat complet treatment remov
miss outcom could overestim treatment effect
view key endpoint total symptom score analysi appear borderlin
signific consid high combin dose
surprisingli low dose miss statist signific wide margin
symptom improv despit eo deplet less high dose
tabl p-valu unorthodox present uninform come
understand rel contribut steroid efficaci
neither placebo respons rate endpoint provid
steroid group shown steroid group omit
patient
random part popul
exclud pp analysi
similar acut steroid use report across
group inform given
cumul dose frequenc dose
subgroup analysi includ steroid group report unusu manner use p-valu
typic one would show respons rate denot statist signific p-valu footnot
visual actual delta respons rate placebo drug group
data
provid
term
rate
better
steroid
antolimab enigma result efficaci eoe subgroup
provid spars data eoe patient direct suggest improv key symptom dysphagia yet
endoscopi find disclos date
evalu subset patient
enigma studi concomit eoe eos/hpf histori
eoe baselin dysphagia
baselin characterist appear skew
arm appear milder group patient
less eo placebo arm less mast call
lower dysphagia score placebo arm
placebo arm exclud one patient
analysi due baselin count eosinophil
given mean eosinophil baselin eosinophil
post-treat vs patient placebo
patient eos/hpf
patient eos/hpf
patient eos/hpf
patient eos/hpf
placebo patient eos/hpf
placebo patient eos/hpf
post-treat vs reduct mean
dysphagia score patient placebo arm
endoscopi find non-specif eg/eg
well-character featur score system
eoe none provid
well-
character eoe
includ fix ring
edema strictur
shown left
exampl mild
moder sever
fix ring eoe
irr found occur major patient first infus bring hassl premed long
infus time risk seriou reaction requir hospit
commonli report teae mild-to-moder infusion-
patient vs placebo patient
irr mild-to-moder flush
feel
per manag irr occur first infus
greatli reduc occur subsequ infus
two like explan high rate irr
lysi eosinophil infus
engag freeli circul nk cell
one drug-rel seriou ae report irr
recov within hour sequela
one patient hypereosinophil syndrom eos/l
experienc irr mg/kg
irr frequency/sever may associ higher dose
undisclos phase trial current on-going dose
mg/kg increas mg/kg phase trial
may pose addit advers event
patient premed prednison prior first
dose acetaminophen anti-histamin prior everi dose
although patient phase open-label extens
get infus hour infus time
hour like abund caution mg/kg dose
possibl hope obtain better mast cell kill
higher dose eo kill max lower dose
phase enigma treatment-emerg patient
protocol phase dose trial one clinic site
antolimab fasenra competitor eg/eg
eg/eg logic entri azn fasenra benralizumab antibodi show massiv eosinophil deplet
zero blood gi tissu hypereosinophil patient
benralizumab hypereosinophil syndrom rare diseas
eosinophil extrem elev cells/l
eosinophil infiltr multipl organ caus varieti
double-blind placebo-control portion
trial
patient receiv benralizumab mg sc match
placebo arm week
primari endpoint percentag patient achiev
reduct absolut eosinophil count week
benralizumab vs placebo
benralizumab reduc blood eosinophil
major patient despit extrem high
baselin level cells/l
given magnitud eosinophil deplet
allk bring modest mast cell
reduct tabl differenti factor
blood eosinophil deplet benralizumab hypereosinophil syndrom
eosinophil count
tissu biopsi benralizumab also
exce enigma cutoff select
eosinophils/hpf
notabl benralizumab dose monthli
sc inject avoid lengthi iv infus
potenti irr associ
gi tissu eosinophil deplet benralizumab hypereosinophil syndrom
antolimab dupix competitor eoe
regn/sni dupix dupilumab evalu phase trial eoe use robust batteri eosinophil count
outcom endoscopi histolog score assess efficaci
patient diagnos eoe control ppi
peak cell count eosinophil per high-pow field
least site
patient use system glucocorticoid
month swallow topic glucocorticoid week
screen exclud
random stratifi baselin sdi score
phase studi dupilumab eoe trial design
chang baselin sdi-pro total score
chang baselin eesai-pro score
chang baselin eoe-eref score
chang baselin eoe-hss
patient receiv dupilumab sc mg weekli
load dose mg day match placebo
allergen immunotherapi prohibit
patient rescu medic esophag
dilat treat non-respond
esophag eosinophil count proxim
mid distal region eos/hpf mean sd
compar eoe patient enrol allk phase trial eosinophil count
baselin dupilumab phase trial higher cells/hpf vs cells/hpf
baselin dysphagia wors suggest sever patient popul
endoscop refer score eoe-hss eosinophil esophagitis-histolog eoe-qol-a eosinophil esophagitis-qu life-adult hpf high-pow field sc subcutan
antolimab dupix competitor eoe
dupix dupilumab significantli reduc eosinophil count eoe patient correl multipl measur
endoscop histolog improv
eosinophil count reduc
dupilumab-tr arm modestli increas
placebo-tr arm
histolog remiss defin eosinophil
week
vs dupilumab- vs placebo-tr
correl eosinophil reduct
improv
seen eref score eoe-hss grade score
eoe-hss stage score
kol state eosinophil count alon
complet measur eoe activ
eosinophil reduct cell count
chang eref score baselin
chang eoe-hss grade score
chang eoe-hss stage score
quantif
strictur
quantif
antolimab dupix competitor eoe
cutoff defin symptomat remiss
respons show
perfect
predictor
highlight need
sdi primari endpoint amend
week due e-diari malfunct
lost data week
sdi score improv dupilumab vs placebo week
sdi score significantli improv point
dupilumab-tr arm vs point
symptomat remiss defin
eesai score week
sdi score reduct point week
use either scale higher percentag
remiss week vs placebo-tr patient
vs patient dupilumab vs placebo
achiev eesai score
vs patient dupilumab vs placebo
achiev decreas point sdi
antolimab phase trial chronic urticaria
gener direct posit data chronic urticaria although evolv competit landscap suggest
new therapi releg third-lin usag
patient popul trial design
adult patient enrol diagnosi cu least
three month refractori antihistamin treatment singl
fold dosag uct score time enrol
four cohort includ csu xolair-nav csu
xolair-refractori cholinerg urticaria
patient remain antihistamin throughout studi
control hive iss itch pce fric test
csu consid approv endpoint csu
cholinerg urticaria pce test use stationari bike treadmil
elicit hive itch
scratch skin elicit hive itch
baselin characterist xolair-nav xn xolair-refractori xr cholinerg
urticaria cholu symptomat dermograph sderm patient
improv mean score
respons rate defin iss rang
mean score dose
respons rate defin hive pce test
hope posit front-lin biolog treatment
success xolair antihistamine-refractori chronic urticaria
on-going phase trial ligelizumab head-to-head
xolair suggest third-lin set realist
phase trial design chronic urticaria
antolimab ligelizumab competitor chronic urticaria
novarti ligelizumab efficaci look formid csu base phase trial show improv
control hive improv control symptom omalizumab
patient popul trial design
ligelizumab next-gen anti-ig antibodi develop
age
novarti potenti
phase dose-rang trial patient csu
refractori anti-histamin nave xolair enrol
minimum score enrol symptom
free well-control mild moder
patient random receiv ligelizumab sc mg
mg mg singl dose ligelizumab sc
mg omalizumab mg placebo week
primari endpoint complet hive respons weekli
key secondari endpoint complet control
symptom weekli week
week total patient treat
mg mg mg respect ligelizumab complet
hive respons vs omalizumab placebo
week total patient treat
mg mg mg respect ligelizumab complet
control symptom vs omalizumab placebo
base promis result seen novarti advanc ligelizumab
phase trial recruit patient world-wide
dose taken forward phase like mg
week
complet control symptom
phase trial design ligelizumab csu
efficaci ligelizumab control
hive approxim doubl
omalizumab
dose respons curv ligelizumab vs omalizumab hive
antolimab phase trial indol systemat mastocytosi
produc symptom improv indol system mastocytosi ism although lack object endpoint
placebo control make subject data hard assess
patient popul trial design
complet open-label singl ascend dose multipl
ascend dose studi ism patient
adult patient enrol confirm diagnosi ism
base world organ criteria
baselin patient present
least one
follow
patient mg corticosteroid exclud
concomit treatment premed prior infus
specifi trial design
activ
symptom improv seen three scale msq
mc-qol msq proprietari
howev object endpoint report tryptas
level incid anaphylaxi
appear provid level symptom improv
safe/well-toler ism patient
intrigu higher dose mg/kg induc
sever irr howev unclear whether patient receiv
premed prior infus
phase trial design ism
antolimab masitinib competitor ism
ab scienc masitinib show efficaci phase trial sever symptomat ism patient clear unmet need use
subject symptom object clinic sign endpoint
patient popul trial design
masitinib oral administ tyrosin kinas inhibitor
modul activ mast cell macrophag
ab scienc develop masitinib
indol
random placebo-control phase trial
complet sever symptomat ism
protocol amend allow enrol ism
patient sever baselin symptom great
medic need order justifi benefit-risk profil
masitinib induc sever neutropenia skin toxic
inclus criteria
random done increas probabl success
verif
stabl dose concomit
patient receiv treatment masitinib mg/kg/day
two daili dose week
primari endpoint cumul respons least
four sever baselin symptom mast cell
one
asthenia week
ab scienc conduct phase confirmatori studi sever
respons defin improv
object endpoint includ chang tryptas level
optim patient popul exclud cutan mastocytosi
appli dose titrat increas toler exclud measur
fatigu impact scale appear insensit chang
urticaria pigmentosa darier sign
expect read
antolimab phase trial sever allerg conjunct
substanti reduc ocular symptom among sever subtyp sever allerg conjunct though conclus
limit lack placebo control small patient number
patient popul trial design
address key mediat allerg conjunct
deplet eosinophil inhibit mast cell
adult patient enrol confirm diagnosi akc
vkc pac averag total ac score calcul
daili ac questionnair
sensat eye water exclud symptom atop
dermat allerg asthma allerg rhiniti
patient histori corticosteroid use treatment
phase outcom sac
stabl concomit treatment allow throughout studi
comorbid found patient includ atop
although patient number small month treatment greatli
dermat asthma rhiniti
reduc total ac score three subtyp
natur cours diseas gener self-limit
symptom tend fluctuat spontan resolv time
placebo control highli necessari confirm drug efficaci
spontan recoveri
time onset action unclear current studi
report endpoint futur studi
fast-act drug desir allerg conjunct given
symptom-driven natur diseas
howev lengthi iv administr /-premed like
non-start market adopt among ophthalmologist
phase trial design sac
antolimab dextenza competitor sac
seek expand usag dextenza steroid-releas insert allerg conjunct
third phase trial one hit one miss two previou trial
expans perenni allerg conjunct
dextenza ophthalm insert place physician
conduct two phase trial evalu dextenza ocular
lower lacrim punctum open canaliculu
itch associ perenni allerg conjunct
singl insert releas mg dexamethason day
dextenza indic treatment ocular inflamm pain
insert fulli resorb day requir remov
dextenza elimin hassl administ steroid eye
drop post-surg period ocular procedur
launch dextenza juli appear
good start doc reimburs product separ
surgeri bundl payment plu fee place insert
estim peak annual revenu
reimburs hopd set
signific improv ocular itch placebo
minut allergen challeng day insert
second phase trial june neg miss
timepoint attribut greater variabl ocular itch
exhibit patient compar first trial
third phase trial conduct use
protocol endpoint first two trial
expect readout posit would file
approv perenni allerg conjunct
estim much larger market opportun allerg
conjunct dri eye collect annual
administr done physician offic set
placement dextenza insert within lower lacrim punctum
dextenza approv indic plan label expans
initi coverag under-perform
inc incom statement valu mm except ep averag net sale net sale net sale net sale expens oper expens product oper loss incom expens interest incom expens incom expens incom expens profit loss incom tax expens incom gain loss market secur net incom loss per share attribut common averag share outstand averag share outstand
inc balanc sheet valu mm except ep averag assetscash cash market expens current current asset properti equip leas right-of-us long-term stockhold equiti liabil current liabil account expens current current liabil debt long-term total equiti stockhold deficit addit comprehens gain total stockhold equiti liabil stockhold equiti
inc statement valu mm except ep averag flow oper activ net incom reconcil net incom loss net cash use oper activ depreci compens tenant improv amort premium discount market leas oper asset liabil prepaid expens current long-term expens current long-term cash use oper flow invest activ purchas properti market matur market cash use invest flow financ activ proce exercis stock issuanc common stock net issuanc issuanc common stock repay recours promissori defer financ issuanc convert prefer stock promissori note net issuanc facil net cash provid financ increas cash cash equival restrict cash equival restrict cash begin cash equival restrict cash end
inc discount analysi valu tax stock compens capit chang work free cash
initi coverag under-perform
origin eg/eg unclear believ allerg compon involv unknown food trigger lead
patholog infiltr gi tissu eosinophil
diseas background pathogenesi
eg/eg inflammatori disord character eosinophil
empir elimin diet decreas allergen exposur
infiltr stomach and/or duodenum case
pathogenesi eg/eg well understood
epidemiolog clinic featur suggest allerg compon
food exposur believ activ drive differenti il-
cell eg/eg lead gut eosinophilia
tract abl
eosinophil recruit gastrointestin
releas eosinophil-act cytokin cytotox protein
also report observ mast cell elev
absenc eosinophilia symptomat patient
small percentag patient eg/eg remit complet
rare eg/eg also report remit spontan
patient period flare month year
patient complianc main limit dietari therapi
glucocorticoid decreas gastric/duoden inflamm
prednison typic mg/day
use minimum dose need amelior sever
symptom rather use high dose control tissu eosinophilia
low-dos mainten therapi mg per day
need patient recurr symptom
histolog find eg/eg
endoscop find eg/eg
joseph et al american colleg gastroenterolog uptod
histolog find infiltr eosinophil lamina propria endoscop find nodular polypoid mucosa antrum
phase enigma screen reveal sizabl popul eg/eg patient
pure mast cell elev
eoe trigger food allergen result patholog infiltr esophag tissu eosinophil small subset
eoe patient concomit eg/eg sign symptom well
diseas background pathogenesi
eoe chronic immune/antigen-medi esophag diseas
character symptom relat esophag dysfunct
esophagu normal devoid eosinophil
antigen protein typic deriv food trigger adapt
cell-medi respons esophagu
cytokin produc recruit eosinophil
tissu
peripher blood esophag
activ
increas number mast cell also seen esophag
tissu sampl degranul common
half patient eoe occur absenc
blood eosinophilia occur eoe
typic mild
magnitud cells/l blood
elimin element diet decreas allergen exposur
patient respond well ppi treatment
topic glucocorticoid decreas esophag inflamm
typic fluticason budesonid mg/day
symptom usual reliev day first dose
remiss last month
small proport patient relaps steroid requir
histolog find eoe
endoscop find eoe
eoe biopsi reveal increas number eosinophil mast cell rel
non-diseas esophag tissu
margaret et al frontier uptod maura et al research melina et al campaign urg research eosinophil diseas
histolog find arrow eosinophil epithelium esophag biopsi endoscop find arrow deep mucos tear mid-esophagu
csu autoimmune/inflammatori diseas distress symptom self-limit major patient
effect treat antihistamin xolair remaind
csu defin presenc urticaria hive angioedema
day week period week longer
underli caus remain unclear well develop
theori involv histamine-releas factor defect basophil
histamine-releas factor blood capabl activ mast
lesion swell itchi area surround erythema
cell basophil increas permeabl blood vessel
return normal minut hour
angioedema episod submucos subcutan swell
affect lip cheek periorbit area face etc
anoth theori highlight autoimmun origin given circul
ige high-affin ige receptor
autoantibodi
detect csu patient
system symptom headach fatigu pain swell joint
mast cell number normal
skin csu patient
wheez flush gastrointestin symptom palpit
releas histamin readili healthi individu
csu associ autoimmun diseas lupu
celiac diseas sjgren syndrom
csu self-limit diseas major patient
csu patient also demonstr basophil respond
respons observ symptom improv
activ
spontan remiss occur patient one year
averag durat diseas two five year
patient symptom beyond five year
antihistamin remain initi approach therapi
patient respond suffici requir treatment
antihistamin fail xolair omalizumab one
best second-lin option report complet respons rate
howev treatment suppress symptom
chang natur cours diseas
patient fail antihistamin xolair
effect agent current cyclosporin
ism character abnorm prolifer mast cell good prognosi despit varieti debilit
symptom although progress sever malign form
system mastocytosi group prolif disord
character mast cell accumul activ multipl
ism common form system mastocytosi involv
extracutan site frequent bone marrow
mastocytosi result clonal neoplast prolifer
morpholog immunophenotyp abnorm mast cell
excess chronic episod mast cell mediat releas
commonli due kit mutat increas express stem cell
factor molecular aberr etc
ism follow stabl slowli progress clinic cours
carri good prognosi patient median surviv
measur decad
clinic present commonli involv varieti symptom
relat organ dysfunct
syncop dizzi diarrhea vomit depress headach
increas
toward advanc form end mast cell leukemia
individu therapi focu prevent mast cell activ
mitig symptom occur
antihistamin antileukotrien drug cromolyn
sodium common option major ism patient
mg daili steroid week use recurr
anaphylaxi episod breakthrough mast cell activ
symptom occur anti-histamin treatment
flush osteoporosi
depress may ad standard anti-inflammatori regimen
necessari
intervent
preval common symptom ism
diseas progress system mastocytosi
case allerg conjunct address over-the-count medic bothersom symptom rare
sever subtyp requir topic corticosteroid prevent loss vision
allerg conjunct ige-medi hypersensit reaction
caus mast cell degranul secondari direct contact
allergen ocular surfac
mild case allerg conjunct notic bothersom
symptom due red itchi eye otherwis harm
ocular surfac caus visual
immedi respons mediat predominantli mast cell
present high concentr conjunctiv epithelium
increas patient allerg conjunct
late phase begin influx
eosinophil basophil neutrophil attract
cytokines/chemokin releas mast cell
chronic allergi differ acut form mediat primarili
cellular factor
impair promptli treat
patient discourag rub eye caus
mast cell degranul worsen symptom
mild case over-the-count topic anti-histamin mast
tear cold compress
usual adequ address symptom
depend upon activ immun cell basophil
eosinophil infiltr conjunctiva prolong
sever case especi vkc akc topic corticosteroid
drop use although prolong use caus increas
acut allerg conjunct sudden-onset hypersensit
reaction resolv promptli remov allergen
season allerg conjunct gradual cours
correspond specif pollen season
perenni allerg conjunct mild chronic conjunct
relat environment exposur year-round allergen
vernal keratoconjunct vkc sever form appear
children adolesc season recurr hot dri
climat tend resolv puberti
atop keratoconjunct akc sever form affect
patient atop dermat season fluctuat sever
akc corneal ulcer
vkc giant papilla
initi outperform topic gene therapi platform
innov hold potenti beyond diseas
gene therapi compani stand apart other field due uniqu approach
use herp simplex vector topic deliveri skin diseas compani
made rapid progress promis data lead indic ultra-rar blister disord known
dystroph epidermolysi bullosa deb manag seek approv launch
therapi deb two addit orphan indic pipelin core busi
expect remain concentr rare diseas potenti out-licens platform
develop aesthet product would compet botox inject filler well packag
monoclon antibodi topic use initi outperform rate price target
star-d platform bring gene therapi dermatolog start ultra-rar diseas highest
unmet need proprietari method leverag natur propens infect skin cell creat
modifi vector capabl transfer larg kb gene payload sinc dermatologist known
cautiou drug safeti profil non-integr non-repl natur featur
lessen concern erron genom insert viral shed respect logic entri point
pursu trio ultra-rar monogen skin diseas clinic proof-of-concept vector deb
autosom recess congenit ichthyosi arci netherton syndrom replac defect gene
diseas theoret result improv skin appear clearli discern
posit result could simultan de-risk platform increas confid abil expand
aesthet condit and/or common skin diseas atop dermat psoriasi
swift pace develop could see first gene therapi deb reach clinic conduct
phase trial deb patient show substanti benefit time complet wound
closur percentag wound closur durat complet closur although small sampl size
visual improv heal vs placebo-tr wound month strike
manag expect initi singl pivot phase trial enrol deb patient
top-line data file bla given prioriti review fda could approv
soon current approv therapi deb lead pack develop
view closest competitor abeo autolog ex vivo gene therapi function akin
skin graft may appropri larger wound abeo phase trial on-going expect
complet due complic manufactur treatment process
await catalyst arci netherton unlock near-term valu view approv deb
increasingli price stock also reflect valuat high probabl success
asset catalyst interim readout arci expect ind file netherton
also plan could potenti set interim data arci netherton
estim remain conserv given preclin data avail albeit express function protein
skin look favor furthermor indic present less sever phenotyp compar deb
think limit price power use risk-adjust dcf valu pipelin ascrib
valuat deb arci netherton also ascrib
star-d platform recogn potenti applic beyond immedi pipelin
outperform
tabl content
debat investor
valuat market opportun
initi coverag outperform
execut summari
clinical-stag biotechnolog compani engag develop gene therapi dermatolog diseas compani
found krish suma krishnan april headquart pittsburgh pa septemb complet ipo ceo
krish krishnan previous involv two success biotech ipo intrexon compani
proprietari platform star-d produc topic gene therapi well pipelin three program two clinic one preclin
star-d gene therapi platform patent fulli integr method gener modifi herp simplex vector
capabl deliv target gene directli skin vector possess sever advantag includ larg payload capac
kb vs kb median protein-cod gene non-integr avoid erron insert host cell dna non-repl
allow repeat dose without concern viral shed beyond initi focu monogen ultra-rar skin diseas potenti
platform appli aesthet defect common skin condit
modifi vector carri type vii collagen gene mutat dystroph epidermolysi bullosa
deb loss lead separ epidermi dermi format sever eros blister predispos patient
infect squamou cell carcinoma earli death phase trial wound demonstr faster time complet
closur greater percentag closur longer durat compet closur compar placebo-tr wound three month
almost wound fulli close placebo-tr wound mostli fail heal remain open manag
swiftli proceed singl pivot phase trial expect top-line data plu file bla fda approv
modifi vector carri gene common mutat autosom recess
congenit ichthyosi arci loss prevent proper crosslink extracellular protein outermost layer epidermi
stratum corneum caus thick dri scali skin cover whole bodi preclin model show treatment
induc express function protein detect correct skin layer abl crosslink substrat
protein interim clinic readout on-going phase trial expect
modifi vector carri serin proteas inhibitor kazal-typ gene mutat netherton
syndrom loss allow unregul proteas activ outermost layer epidermi stratum corneum present
red inflammatori scale across entir bodi characterist bamboo hair preclin model show treatment
induc express function protein detect correct skin layer abl inhibit proteolyt damag
manag plan file ind order advanc first-in-human studi
valuat arriv per share price target outperform rate
execut summari
tickerkrysratingoutperformpric target price rang cap outstand total revenu ep
debat investor
initi coverag outperform
debat investor
fit treatment landscap deb sever competitor therapi pipelin
potenti come market
half dozen therapi develop see best prospect deb view
two asset compel efficaci address distinct patient need like first-to-market
think pole posit given robust perform wound complet close within day wound complet close
day averag eas applic topic off-the-shelf therapi vs autolog ex vivo approach
one wound type may amen abeo skin graft approach larg wound tend non-heal
stay open chronic abeo gene-correct autolog epiderm sheet measur cm multipl sheet
use address larg wound sever hundr size
two largest wound treat phase trial fulli close day respect
plan assess smaller recur wound larger chronic wound pivot phase trial think evalu
wound unclear plan tackl largest wound clinic trial set
translat wound size
unclear volum topic gel need
illustr time cours recurr wound
natur histori studi rdeb wound
illustr time cours chronic wound
phase trial target
pfu per day target wound cover
area presum titer
viru particl given volum would need
maintain avoid sacrif efficaci
real-world set deb see role
product
abeo graft larger wound
smaller wound spot
treatment breakdown area larger wound
post-engraft prolong life graft
compani report compani file clintrial gov eichstadt et al insight teng et al abstract societi investig dermatolog annual meet soli et al journal
debat investor
remaind rare diseas pipelin arci netherton syndrom replic
market opportun deb
indic pursu unmet need approv therapi underli pathogenesi deb
creat sever phenotyp arci netherton syndrom
deb loss prevent format anchor fibril need join epidermi underli dermi full separ
epidermi dermi creat sever eros blister open wound risk infect frequent progress squamou
cell carcinoma patient life expect usual two three decad
arci netherton syndrom outermost layer epidermi stratum corneum disrupt lose natur barrier function
abil retain moistur neonat period patient high risk infect potenti life-threaten complic
patient get older symptom typic moder life expect normal
cost palli treatment estim deb awar formal cost estim arci
netherton syndrom assum lower cost due lesser diseas burden
model higher annual gross price vs base case scenario
given arci netherton affect entir bodi surfac area vs discret lesion deb volum topic gel usag could highli variabl
damag lost
damag lost deb
layer epidermi
assumpt revenu model eu annual price
complianc eu net price discount
comparison damag lost skin deb vs arci netherton
debat investor
upsid star-d platform beyond sever monogen rare diseas consid applic
aesthet condit chronic common skin diseas
aesthet condit facial aesthet market wrinkl fold lip/cheek/chin augment sizabl current domin
allergan product annual botox inject dermal filler set high bar efficaci safeti cost
procedur paid out-of-pocket market dynam heavili driven brand-nam recognit
botox use titrat dose neurotoxin temporarili freez facial muscl relax overli skin elimin wrinkl room
provid natur look artifici facial express sometim occur due lack muscl movement numer competitor
neurotoxin enter close enter market dysport galderma xeomin merz jeuveau daxi revanc
inject dermal filler semisolid gel contain collagen hyaluron acid biopolym design replac lost collagen volum
age skin allergan market six product part juvederm franchis competitor includ restylan sculptra galderma radiess
belotero merz teosyal franchis teoxan
await clinic proof-of-concept data determin
intraderm gene therapi compet efficaci
durat effect month botox month filler given long safeti record botox filler cosmet physician may
slow adopt novel modal gene therapi better understand potenti advers event
allergan q/q y/i growth facial aesthet
chronic common skin condit tradit dichotomi topic agent corticosteroid mild-to-moder diseas
vs system therapi biolog moderate-to-sever diseas topic monoclon antibodi would presum
enhanc local potenc abil address larg affect bodi surfac area may compromis remain skeptic
exclud revenu botox therapeut indic non-cosmet usag
juvederm franchis xc voluma xc vollur xc volbella xc ultra xc ultra xc
valuat market opportun
initi coverag outperform
arriv price target base risk-adjust discount cash flow dcf model assum
weight averag cost capit wacc termin growth rate share outstand million
valu dystroph epidermolysi bullosa deb autosom recess
congenit ichthyosi arci netherton syndrom skin target deliveri star-d gene therapi platform
present includ aesthet skin condit common chronic skin condit valuat
asset repres upsid current estim
dcf discount cash flow wacc weight averag cost capit deb dystroph epidermolysi bullosa arci autosom recess congenit ichthyosi
assum market entri deb estim peak sale million appli risk
discount arriv risk-adjust peak sale million
assum eu market entri deb estim eu peak sale million appli risk discount
arriv risk-adjust peak sale million
assum market entri arci estim peak sale million appli
risk discount arriv risk-adjust peak sale million
assum eu market entri arci estim eu peak sale million appli
risk discount arriv risk-adjust peak sale million
assum market entri netherton syndrom estim peak sale million appli
risk discount arriv risk-adjust peak sale million
assum eu market entri netherton syndrom estim eu peak sale million appli
risk discount arriv risk-adjust peak sale million
assum technolog platform valu million star-d platform recogn potenti modifi vector
treat varieti skin diseas topic gene therapi
star-d platform applic beyond treatment sever monogen skin diseas could includ aesthet defect
chronic common skin condit posit proof-of-concept data would incorpor addit indic valuat
 eu market entri deb
 eu peak sale
 million risk-adjust
trial deb deliv
deb
trial deb deliv
valuat adjust oper
 eu market entri
arci
 eu peak sale million
risk-adjust discount
 eu market entri
netherton syndrom
eu peak sale million
risk-adjust discount
technolog platform valu million
star-d gene therapi platform
phase trial
data reduc risk-adjust
arci discount
phase trial
data remov valuat
ind file phase
trial netherton syndrom
netherton
syndrom discount
phase trial netherton
remov valuat adjust
success
across clinic trial reduc risk
adjust individu note
failur
trial model
across clinic
adjust individu note
failur on-going clinic trial deb arci and/or netherton
syndrom may impact estim target price and/or rate view phase studi substanti de-risk deb
expect pivot trial follow similar design low likelihood all-out failur howev studi
enrol rdeb subtyp wherea pivot studi includ ddeb rdeb subtyp expect
seek broad label deb inclus subtyp label could exclud ddeb result materi weaker rdeb
given arci netherton syndrom yet report clinic proof-of-concept data appli appropri conserv risk
fda ema and/or ex-u regulatori agenc may delay and/or deni approv deb
defici arci and/or netherton syndrom given orphan natur unmet need skin diseas
expect acceler regulatori pathway three asset case think fda/ema permit singl pivot trial
enrol single-to-low-double-digit patient number bypass full phase program sinc arci netherton
syndrom present rel less sever phenotyp compar deb possibl fda/ema may stringent
requir approv two indic
loss first-mover/competit advantag and/or commercial/govern reimburs deb
defici arci and/or netherton syndrom may impact estim target price and/or rate expect
seek commerci asset approv hiring/deploy salesforc except partner given small
size address popul rare diseas think feasibl effect launch product
eu without partner think deb command greater price power arci netherton
syndrom base morbidity/mort associ diseas
competitor product approv market prior and/or competitor superior
therapeut profil asset could advers impact deb compet investig product
phoenix tissu repair aegl rheacel arci netherton syndrom
awar on-going company-sponsor trial though investigator-sponsor trial previous and/or
current evalu biolog retinoid
depend cash flow statu probabl success develop deb
arci and/or netherton syndrom compani may need rais addit fund financ sg
activ come year model next equiti rais
deb dystroph epidermolysi bullosa ddeb domin deb rdeb recess deb arci autosom recess congenit ichthyosi fda food drug administr
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
deb popul age y-o-i growth live birth new patient rdeb ddeb live number patient rdeb ddeb patient treat market y-o-i annual price/rx price annual revenu deb growth popul age y-o-i growth live birth eu new patient rdeb ddeb live number patient rdeb ddeb eu patient treat market y-o-i annual revenu deb eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
arci popul age y-o-i growth live birth new patient arci live number patient arci patient treat market growth annual price/rx price annual revenu arci growth popul age y-o-i growth live birth eu new patient arci eu number patient eu patient treat market growth annual revenu arci eu growth
revenu risk-adjust discount
revenu risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
netherton syndrom popul age y-o-i growth live birth new patient netherton syndrom live number patient netherton syndrom patient treat market growth annual price/rx price annual revenu netherton syndrom growth syndrom popul age y-o-i growth live birth eu new patient netherton syndrom live number patient netherton syndrom eu adult patient treat market growth annual revenu netherton syndrom eu growth
initi coverag outperform
chairman chief execut offic
founder chief oper offic
krish krishnan accomplish biotech
execut specif involv
two success ipo coo/cfo new
intrexon approv blockbust drug
vyvans adhd sale
new river
shire billion serv
ceo pinnacl pharmaceut
advanc potenti treatment urinari
tract infect discoveri phase ii
serv board member bioti
develop compani finland
prior sale
grunenth gmbh previous
krish serv manag princip
marketplac sold ariba
krish start career
senior engin dupont de
nemour krish undergradu
degre indian institut
technolog graduat degre
financ wharton school
univers pennsylvania
multipl
suma krishnan year drug
program discoveri clinic
develop approv vyvans
blockbust drug treat adhd svp
new river
suma
advanc approv adderal xr
fosrenol shire began career
discoveri scientist
janssen
pharmaceut suma
public issu us patent
receiv master scienc
villanova
univers
institut
manag research
chemistri ferguson univers
ms kathryn romano recent
corpor control resourc
join ms
romano corpor control
rice energi januari
compani acquir
novemb stay assist
transit
march prior join rice energi
work varieti account
audit role black corpor
deloitt ms romano certifi
public account hold bachelor
degre account state
appoint kathryn romano
chief account offic base
headquart pittsburgh pa
also announc toni riley
chief offic
jennif chien year
leadership experi
recent vice presid head
genet diseas sanofi genzym
respons
commerci strategi implement
seven brand prepar
tenur sanofi genzym
leadership role vice-president
head global nephrolog diseas
access intern market
addit
hold degre massachusett
institut technolog mph degre
harvard univers
initi pivot trial deb enrol ddeb rdeb patient
rdeb
top-line data pivot trial deb
submiss bla approv deb
initi pivot eu trial deb enrol ddeb rdeb patient
interim clinic readout arci data patient expect
file ind begin clinic studi netherton syndrom
aesthet skin condit file ind begin clinic studi aesthet skin condit
top-line data trial rdeb
jeb deb adult
top-line data trial inherit form eb includ deb
rdeb exon top-line data trial rdeb exon mutat
jeb deb
top-line data trial jeb deb
top-line data viital trial rdeb
top-line data defi-rdeb trial rdeb
top-line data trial deb
top-line data trial rdeb
initi trial netherton syndrom
initi coverag outperform
star-d platform gener therapeut vector base herp simplex provid versatil
mean develop drug skin diseas
non-integr non-repl
transduct effici cell-bas studi
avoid risk disrupt host gene
enabl direct deliveri skin topic gel intraderm solut
transient express dilut cell divis
scalabl reproduc manufactur
deliv kb provid room large-s gene
impact product yield higher payload
compliant global regulatori standard gene therapi product
star-d gene therapi platform vector skin diseas
leverag engin gene vector high transduct effici skin low immunogen high
stabil easili manufactur
attract characterist gene vector
caus agent oral herp cold sore
sexual transmit infect caus genit herp
wild-typ larg viru kb highli infecti
invad replic skin mucou membran neuron
abil infect non-divid divid cell
express larg transgen make ideal vector
immedi earli viral gene strateg delet render hsv-
non-tox non-repl non-integr
gene delet also open space transgen payload kb
wherea viral vector engin use dermatolog
diseas accommod kb
upon entri cell engin vector persist
episom unit nucleu remain physic separ
host cell chromosom integr host dna risk cancer-
caus disrupt host gene
abil evad host immun system make
vector safer repeat administr
endem global peopl world-wide
america immunolog evid infect
remain latent
symptom
year
reactiv ill emot stress trauma trigger
unclear cell latent infect wild-typ viru
transduc engin vector could recombin genet materi
mechan action
also known bercolagen telserpavec design off-the-shelf topic gene therapi
repeatedli appli wound dystroph epidermolysi bullosa deb monogen orphan skin diseas
high payload capac vector allow insert two gene copi facilit increas express
topic gel requir special train equip readi appli off-the-shelf
vector penetr intact skin wound need reopen applic topic gel possibl
vector present life cell persist depend turnov rate transduc cell
preclin studi demonstr protein express ex vivo sampl rdeb patient format
anchor fibril mous model rdeb
express
keratinocyt
transduct
immunofluoresc two antibodi red
green demonstr linear deposit protein
basement membran zone enhanc structur integr
electron microscopi rdeb mous skin demonstr
format nascent anchor fibril use two antibodi
domain domain
phase trial design interim result
first-in-human result demonstr acceler durabl wound heal accompani molecular correct
express anchor fibril format
primari endpoint express presenc
anchor fibril safeti
secondari endpoint chang wound area durat
number wound treat
wound closur time wound closur
patient enrol age year old
time complet wound closur week
durat wound closur month
wound closur month
patient wound surfac area
random receiv either topic
placebo total wound evalu
initi dose day repeat dose month later
patient addit dose day day
pi understand impact increment dose
wound evalu clinic
relev heal compar placebo-tr wound
baselin
also inject intraderm patient
intact skin evalu mechan action
valid molecular correct
patient evalu express
anchor fibril electron microscopi
patient also monitor gener
recombin viral infect autoimmun respons
evalu
patient illustr wound heal vs placebo-tr wound
phase trial design pool phase result
across total patient date continu show promis efficaci key clinic endpoint percentag
wound closur time wound closur durat wound closur
wound close complet treatment
primari endpoint percentag wound closur time
averag time complet wound closur day median
wound closur durat wound closur
day wound
secondari endpoint express evid
averag durat complet wound closur day median
anchor fibril
day wound
patient initi enrol adult age
year old pediatr age year old
initi patient wound treat
wound initi close re-dos close
complet within day re-dos open year
remain close day
regard addit patient later enrol phase studi
baselin wound rang
initi patient dose day
pfu/day re-dos day
visibl wound remain origin administr site
patient on-studi month month
on-sit visit follow at-hom
drop studi day due
inabl travel clinic site
addit adult patient age year old
later enrol
addit patient wound treat
addit patient dose everi day
week wound close complet
time complet wound closur wound day
averag durat wound closur timepoint day
patient illustr wound heal vs placebo-tr wound
patient-level data trial
data individu patient trial reveal rapid onset complet wound closur within day
complet closur maintain day recur wound
day
durat
closur
drop drop drop
drop drop drop
drop drop drop
drop
drop
redos day wound close within day remain close day
wound less week old open close spontan
wound remain open greater week
mechanist data safeti
mechan action success translat preclin clinic studi drug appear safe
well-toler six month far repeat dose
molecular correct establish patient across phase trial correl wound heal
patient illustr stain immunofluoresc basement
membran zone skin
patient illustr presenc anchor fibril electron microscopi
basement membran zone skin
continu well
toler follow initi
blood urin sampl collect throughout studi reveal
treatment-rel advers event seriou otherwis
report
immun respons blister observ around site
administr follow first repeat dose
advers event associ routin lab chemistri
antibodi detect
strength limit
perform larger chronic wound efficaci ddeb patient drop-out rate among small sampl size
potenti hurdl could appear pivot trial
complet wound closur within day
recur wound tend heal albeit
treatment almost recur wound
appear greatli acceler heal process
mean time closur day median day
per wound recur natur
complet closur recur wound maintain
mean durat closur day median day
impli everi mainten dose regimen possibl
recurr wound
wound pre-select base baselin size
treat
treatment placebo
tend larger yet still achiev complet closur
sever wound size treat
demonstr complet closur day
sever wound
remain fulli open day
size treat placebo
treat frequent and/or longer time period may
abl address larger chronic wound
topic applic re-appl conveni
carri non-specialist doc potenti caregiv
safeti profil look clean appropri chronic indefinit
molecular correct demonstr clinic set
satisfi regulatori agenc
phase studi address wound
size wherea rdeb patient also chronic wound
larger averag size
larg chronic wound carri greatest burden infect risk
pain itch urgent treat
expect evalu mix recur chronic wound
pivot trial differ dose schedul like
use base learn final patient enrol
phase studi
administ
prophylact must wait wound reopen sinc
topic gel penetr intact skin
consid develop intraderm formul
could use prophylact contribut
life cycl manag product
pivot studi enrol rdeb milder ddeb
patient latter theoret observ similar
benefit yet formal assess
given one patient drop phase studi due
difficulti travel clinic site could also
occur pivot trial expect enrol patient
patient-report outcom pain control
quality-of-lif metric yet disclos
competitor deb
closest competitor abeo fibrocel ex vivo autolog
gene therapi enter phase studi rdeb
mechan action
direct skin applic
ex vivo correct autolog
ex vivo correct autolog
keratinocyt fibroblast
time diagnosi treatment
treatment
potenti in-hom caregiv
surgic suit inpati gener
consciou sedat
wound closur day
one wound
previous day
redos appear work well one
chronic wound
close day redos
close within day
remain close day
like lower cost
wound closur month
wound closur month
wound closur week
address larg wound
chronic open
year
like compet directli
mainten use
durabl year
engraft wound closur
major wound
efficaci wound closur
week look inferior base
data report date
given larg natur mani chronic wound graft abeo may better approach persist
sever year like best option small-to-mid-s recurr wound
potenti appropri
potenti appropri
addit competitor deb
beyond abeo fibrocel half dozen compani work deb therapi
view minor competit threat narrow scope
bark birch tree
mechan action
modul product ro wound induc
involv broad mechan regener
remodel injur damag tissu
recombin replac
phase eas trial enrol adult
phase trial enrol patient deb
children includ deb jeb kindler
phase trial observ faster heal
improv percentag
wound closur area
appropri support care rather
phase trial evalu wound size
daili topic applic
show restor anchor fibril
wound heal iv-administ
efficaci endpoint time achiev
closur percentag wound
closur
crossov trial design evalu dose
salin control vs ascend dose drug
period
hybrid specif sequenc exon
exosom deriv parent msc
mechan action
induc skip exon produc truncat
still function protein
broad anti-inflammatori immunosuppress
immunosuppress properti parent
msc transport mrna protein
dose-depend exon skip efficaci
observ ex vivo-tr epiderm
dermal cell penetr intact skin
inject msc mous
model rdeb partial rescu skin
exosom could captur benefit msc
hard predict control vivo
requir high product cost
phase trial enrol patient least
phase trial enrol patient
phase trial enrol patient
one pathogen mutat exon
dose infus cells/kg
daili topic applic exosom
exon mutat repres
efficaci endpoint evalu itch pain bsa
rdeb patient regist deb databas
suggest small address popul
improv eb symptom week
percentag chang patient ebdasi score
lesion target lesion closur extent
scar lesion heal day
activ scar index mesenchym stem cell bsa bodi surfac area rgrx regenerx prqr proqr therapeut
plan initi pivot phase trial lay necessari groundwork commerci launch
within next month
phase design expect mimic phase trial patient
serv control comparison
conduct natur histori studi
observ deb wound size recurr month
prior enrol patient select wound treatment
primari endpoint like complet closur
pivot phase trial expect begin enrol
report top-line data
phase viital trial abeo closur
baselin treat vs untreat wound week
phase defi-rdeb trial fibrocel complet
wound closur baselin treat vs untreat
wound week
pivot phase trial eu expect initi
bla file deb expect
preced fda approv oncolyt viral
therapi use backbon amgn imlyg talimogen
laherparepvec licens direct
inject
percentag chang wound closur baselin
plan bring manufactur in-hous build
commerci team launch
chang patient global impress wound sever target
wound score higher score indic wors outcom
immunofluoresc biopsi
cgmp manufactur facil ancori pittsburgh pa
astra findley township pa suffici suppli
clinic commerci product
presenc anchor fibril basement membran zone
electron microscopi biopsi
enrol patient
mix rdeb ddeb patient adult pediatr patient
dose pfu per wound allow redos defin
interv wound close
separ dose schedul recur vs chronic wound
timelin clinic develop
mechan action
off-the-shelf topic gene therapi develop autosom recess congenit
modifi vector deliv gene topic gel use similar manner deb
express need correct format anchor outermost epiderm layer stratum corneum
vitro assay immort primari arci cell line deriv patient demonstr protein express
dose-depend increas protein level upon
infect seen immort normal human
defici arci human keratinocyt detect protein
made blot immunofluoresc
dose-depend increas protein level upon
infect seen patient-deriv defici arci
keratinocyt transduct effici appear
rel less primari cell cultur vs immort cell line
dose-depend increas function
detect follow infect patient-
activ measur use fluoresc
peptid detect presenc
signal indic crosslink
substrat loricrin involucrin
vivo studi mice demonstr robust express proper local within epidermi
toxic pave way first-in-human studi
shown express properli coloc
loricrin correct skin layer hour topic
applic mice loricrin substrat
marker stratum granulosum/spinosum layer epidermi
effici vector transduct robust express
shown singl administr day repeat
administr day follow day day
topic deliveri balb/c mice
mortal morbid
relev clinic find note
anim surviv schedul necropsi
transient mild edema dose site
note dose recoveri phase
high copi level detect local
dose site copies/ug tissu day
 day repeat dose success
weekli administr pfu/day via topic applic
dorsal skin male femal mice well-toler
arci autosom recess congenit ichthyosi pfu plaque-form unit noael observ advers event level glp good laboratori practic
initi phase trial arci patient expect report interim clinic
readout patient
phase trial enrol adult evalu vs placebo-tr skin area patient
primari investig global assess iga diseas sever week
secondari visual index ichthyosi sever vii scale lamellar standard week viis-l visual scale
repres normal skin repres sever ichthyosi
secondari immunofluoresc microscopi level skin week
clinic diagnosi lamellar ichthyosi
genet diagnosi arci null mutat
individu site iga score target area
arci autosom recess congenit ichthyosi iga investig global assess viis-l visual index ichthyosi lamellar
timelin clinic develop
vitro assay immort human keratinocyt demonstr protein express secret enzymat
action
modifi vector deliv gene topic gel use similar manner deb
arci also known lekti miss defici netherton syndrom
dose-depend increas
protein level upon infect
seen immort normal human
keratinocyt detect protein
made blot
human protein secret
supernat transduc cell shown
elisa-bas quantif secret
depend abil inhibit nativ target
human serin proteas kallikrein
measur enzymat
vivo studi mice demonstr express proper local within epidermi well
histolog intact skin plan ind file
action
modifi vector deliv gene topic gel use similar manner deb
arci also known lekti miss defici netherton syndrom
shown express
properli coloc filaggrin
correct skin layer hour topic
applic mice filaggrin
serv marker stratum
corneum cornifi layer epidermi
normal compar vehicle-tr
skin without signal toxic mice
star-d platform applic aesthet condit
aesthet product gener use star-d platform would boost local product facial collagen lost
normal age result defect wrinkl fold
plan file ind begin clinic develop aesthet skin condit
manag intend conduct small proof-of-concept studi prior seek partnership develop
facial skin age defect caus loss collagen henc rational boost collagen express
intraderm inject must use sinc modifi vector penetr intact skin healthi individu
current treatment option botox varieti inject dermal filler cosmet surgeri
current cosmet inject exemplifi botox dermal filler juvederm set high bar surpass term
efficaci safeti cost
facial wrinkl fold frown line
moderate-to-sever facial wrinkl fold
moderate-to-sever facial wrinkl fold
lip facial augment
mechan action
vector infect keratinocyt
endogen level collagen product
neurotoxin block axon releas
muscl smooth overli skin
steril gel made one sever natur
carbohydr polym act
volum replac lost collagen
effect dynam wrinkl
effect static wrinkl
caus contract muscl
attach overli skin
fold due volum loss sag
work best wrinkl forehead
eye glabellar corner
eye crow feet frown line
work best wrinkl around nose
mouth boost volum hollowed/
durat effect
mean durat day month
deb patient durat cosmet
small number patient treat
far long-term safeti remain
well-toler date phase
trial deb patient
decad physician experi
decad physician experi
million patient treat
million patient treat
cosmet use report fda
rare case accident inject
blood vessel lead stroke
blind scar
non-seri includ lack effect
shed immun
respons detect date
inject site reaction ptosi
tbd expect price competit
botox inject dermal filler
averag per treatment
common facial procedur
averag per treatment
common facial procedur
quickest conveni cosmet
option lunchtim procedur
revers dissolv inject
hyaluronidas unhappi result
herp simplex type vii collagen alpha api activ pharmaceut ingredi deb dystroph epidermolysi bullosa advers event tbd determin
case studi fibrocel aesthet product laviv
fibrocel laviv de-risk approach local increas facial collagen product illustr need remain cost-
competit out-of-pocket aesthet marketplac
fda approv fibrocel laviv azficel-t autolog cell
improv appear moderate-to-sever nasolabi fold wrinkl adult
autolog fibroblast extract patient expand ex vivo fibrocel
manufactur facil local administ facial wrinkl site
fibroblast expans took month follow sever visit intraderm inject
laviv encourag phase result valid cosmet approach boost local
collagen product pursu
primari endpoint proport patient improv wrinkl
laviv vs placebo assess physician
laviv vs placebo assess patient
gener safe well-toler inject site reaction
price premium aesthet market full cours treatment launch
later discount
price point rang consum insur plan reimburs
compar per treatment dermal filler per treatment botox
two year market fibrocel ceas activ promot laviv due poor sale
unsuccess attempt pivot laviv indic burn scar
manufactur oper wound
workflow product administr
laviv sale thousand
first full year sale
fda food drug administr
star-d platform applic chronic common skin diseas
proprietari vector larg enough accommod full-length monoclon antibodi antibodi fragment
could potenti formul topic deliveri atop dermat psoriasi
data show full-length mab dupix packag within modifi vector
manag plan advanc clinic develop topic antibodi formul without partnership
remain unclear chronic skin condit could benefit local deliveri antibodi
hypothet trade-off local deliveri antibodi higher efficaci vs limit reach bodi surfac area
initi coverag outperform
inc incom statement valu mm except ep averag net sale net sale net sale expens oper expens product gener oper loss incom expens interest incom expens profit loss incom tax expens incom gain loss available-for-sal secur net incom loss per share attribut common averag share outstand averag share outstand
inc balanc sheet valu mm except ep averag assetscash cash expens current current asset properti equip non-current stockhold equiti liabil current liabil account portion leas expens current current liabil leas non-current total equiti stockhold deficit addit comprehens incom total stockhold equiti liabil stockhold equiti
inc statement valu mm except ep averag flow oper activ net incom reconcil net incom loss net cash use oper compens dispos fix right-of-us asset interest oper asset liabil prepaid current expens current non-current rent cash use oper flow invest activ purchas properti short-term matur short-term non-current cash use invest flow financ activ issuanc prefer stock prefer common stock issuanc convert promissori issuanc relat parti convert promissori cash provid financ increas cash cash equival restrict cash equival restrict cash begin cash equival restrict cash end
inc discount analysi valu tax stock compens capit chang work free cash
initi coverag outperform
deb ultra-rar monogen diseas patient suscept sever skin blister treatment
option asid support care
diseas background pathogenesi
anchor fibril compos
adhes epiderm dermal layer skin
gene express produc chain requir
format function anchor fibril tripl helix structur dimer assembl
deb patient mutat gene neg affect synthesi
stabil triplex dimer individu mutat identifi
recess deb rdeb mutat prevent product assembl reduc
build block polypeptid need form anchor fibril occur
intracellularli earliest step process
domin deb ddeb mutat interfer dimer assembl glycin substitut
fulli form anchor fibril occur extracellularli final step process
rdeb sever present involv gener blister skin
mucou membran fragil epidermi easili peel away dermi
open wound rdeb heal slowli patient die age due
infect squamou cell carcinoma common complic
current manag rdeb consist support care pain manag
ddeb less sever mainli affect hand feet knee elbow wound
form ultra-rar nation registri suggest follow
rdeb incid per million live birth preval per million popul
ddeb incid per million live birth preval per million popul
supp et al cell transplant shinkuma et al clinic cosmet investig dermatolog fine et al jama dermatolog chung et al dermatol clin
deb dystroph epidermolysi bullosa rdeb recess deb ddeb dystroph deb type vii collagen fda food drug administr
arci ultra-rar monogen diseas patient epiderm defect result gener skin scale
palli treatment avail
diseas background pathogenesi
manag center support care
arci inherit skin disord character thick dri
scali skin increas trans-epiderm water loss due
defect epiderm barrier format
form arci
ichthyosi li congenit
ichthyosiform erythroderma cie caus mutat
one sever gene
individu mutat found affect mrna
stabil catalyt function
crosslink -hydroxyceramid cornifi cell envelop
termin
differenti keratinocyt form cce structur
import maintain skin barrier function
goal therapi prevent infect manag hydrat
nutrit provid eye care necessari
fda-approv therapi avail arci
emolli mainstay treatment control scale
retinoid acitretin
isotretinoin use
advers effect long-term retinoid therapi includ prematur
closur epiphys calcif tendon ligament
develop skelet hyperostosi osteoporosi
long-term retinoid therapi particularli ill-suit children
bone growth defect pregnant women seek
mutat found case lamellar
unclear much activ requir maintain
petit et al report pmol/ hmg affected/unaffect
skin area patient
record literatur
unaffect heterozygot pmol/ hmg
subject commonli activ level rang
pmol/ hmg
hohl et al societi investig dermatolog inc rodrguez-pazo et al acta dermosifiliogr petit et al ejhg mutat et al mutat huber et al journal
netherton syndrom ultra-rar monogen diseas patient unregul proteas activ
epidermi lead widespread skin inflamm treat symptomat
diseas background pathogenesi
normal epidermi also known lekti inhibit activ serin
proteas form inhibitori complex
netherton mutat gene caus decreased/abs express
consequ proteas activ unoppos downstream epiderm
target lead defect skin barrier format function
excess activ also mediat product pro-inflammatori cytokin
lead gener state widespread tissu inflamm
newborn netherton exhibit diffus ichthyosiform erythroderma high risk
life-threaten complic hypernatrem dehydr hypothermia
patient typic red inflammatori scale face shoulder back well
short brittl broken bamboo hair
patient eventu manifest
ichthyosi lineari circumflexa telltal sign
netherton evolv age milder cutan phenotyp
patient also suffer broad rang allerg symptom predispos skin
manag center support care
specif therapi netherton approv fda far
support care neonat includ monitor
fluid electrolyt bodi
temperatur prevent infect skin care
care skin care age central part manag address symptom
emolli occasion use low-pot topic corticosteroid calcineurin inhibitor
oral antihistamin ivig sever diseas allerg symptom
uptod lacroix et al journal investig dermatolog di et al human gene therapi omim entri
initi outperform under-the-radar lead asset game-
changer type diabet
led season team serial biotech entrepreneur prvb resurrect antibodi
teplizumab shelv disappoint result
type diabet first prvb leverag recent unexpectedli posit data
investigator-sponsor trial teplizumab earlier pre-symptomat patient risk develop
achiev quick approv second compani revisit origin indic newli
diagnos patient better-design -execut phase ph trial potenti expand
delay progress year initi outperform rate price target
teplizumab near finish line at-risk without clinic trial requir fda
indic investigator-sponsor trial at-risk patient along histor efficacy/safeti data
four prior studi conduct mgnx/lli suffici support approv rate-limit step
roll bla submiss final modul prvb expect complet assum
prioriti review launch teplizumab could occur think drug remain underappreci
street investor trial demonstr impress delay two year onset clinic
averag receiv singl cours therapi bar screen at-risk individu
appear low initi launch effort focu direct rel patient dysglycemia
autoantibodi given commerci avail lab test autoantibodi address
popul like grow prvb advocaci group promot screen campaign
lesson learn fail protg trial provid much better odd success newli diagnos
adopt unvalid composit endpoint insulin lax enforc
enrol criteria non-u geographi major limit mgnx/lli protg studi
furthermor fda think shift c-peptid auc reliabl predictor insulin-produc
beta cell capac appropri primari endpoint post-hoc analys protg indic much better
c-peptid preserv patient age year old diagnos within week
enrol prvb adopt criteria plu enrol cutoff c-peptid pmol/ml post-mmtt
select patient like respond teplizumab evid date suggest exponenti declin
c-peptid level within week diagnos design cutoff consid
point return teplizumab effect residu beta cell mass neglig
current level present substanti upsid even remain pipelin assign minim valu one
point prvb assembl pipelin five addit asset beyond teplizumab shrewd in-licens
sever trial miss past year whittl near-term focu teplizumab plu two clinical-
stage asset use risk-adjust dcf valu prvb pipelin ascrib valuat teplizumab
inclus at-risk newli diagnos lupu celiac diseas
interestingli bearish scenario assum failur non-teplizumab asset well one-
year delay regulatori file teplizumab arriv price target in-lin current trade price
therefor think downsid prvb limit accumul hold share ye
reward investor manag execut accord state conserv timelin
outperform
tabl content
debat investor
valuat market opportun
provent prvb initi coverag outperform
execut summari
prvb clinical-stag biotechnolog compani strateg focu autoimmun emphasi immuno-endocrinolog compani
found ashleigh palmer ceo francisco leon cso octob headquart oldwick nj juli prvb
complet ipo manag led season serial entrepreneur long-standing relationship within biopharma industri
enabl in-licens compel portfolio product pipelin consist four program clinic develop
teplizumab monoclon antibodi develop delay/prevent type diabet well
treatment newli diagnos asset origin sub-optim conduct phase trial
result shelv teplizumab resurrect prvb investigator-sponsor phase trial at-risk pre-symptomat
patient recent reveal game-chang benefit wherebi singl cours treatment delay onset clinic two year
averag follow posit fda discuss prvb expect complet submiss roll bla ye addit studi
potenti receiv approv at-risk meanwhil phase protect trial use lesson learn prior studi
stringent enrol newli diagnos popul top-line data expect
coxsackieviru cvb vaccin develop prevent and/or celiac diseas cvb colon signific
proport celiac patient viral antigen thought cross-react trigger autoimmun attack host
tissu ind file phase trial initi plan first-in-human data avail manag envis
target vaccin at-risk patient perhap one day univers vaccin primari prevent
bispecif antibody-bas molecul dart develop use platform given potenti autoimmun
applic right obtain prvb concurr teplizumab drug dualli target cell co-receptor
fcriib inhibit deplet cell prvb advanc phase trial lupu data safeti
cohort expect step would enrol lupu patient demonstr clinic proof-of-concept
monoclon antibodi origin genmab saw right success transfer celimmun
back prvb previou incarn celimmun prvb team ran two phase trial celiac
diseas non-respons gluten-fre diet posit signal efficaci prvb plan phase trial begin enrol
expect top-line data manag see opportun inclus celiac patient look prevent measur
addit refractori patient risk progress small bowel lymphoma
valuat arriv per share price target outperform rate
ipo initi public offer type diabet fda food drug administr bla biolog licens applic ind investig new drug cvb coxsackieviru dart dual- affin re-
execut summari
tickerprvbratingoutperformpric target price rang cap outstand total revenu ep
debat investor
provent prvb initi coverag outperform
debat investor
at-risk type diabet patient identifi real-world practic screen
relat autoantibodi hurdl uptak teplizumab
launch focu famili direct rel patient estimate current patient known doc
appear straightforward identifi first-degre rel specif offspr use criteria phase at-risk trial
screen patient age year older dysglycemia least two autoantibodi
dysglycemia defin fast plasma glucos level mg/dl postprandi glucos level mg/dl interven
postprandi glucos level min mg/dl occas easili assess either fast plasma glucos oral
glucos toler test consum sugari solut hour prior test routin lab test done singl blood draw
major islet
autoantibodi routin use diagnost test howev commerci
autoantibodi ica avail multipl vendor current use confirm borderlin
diagnosi rare case unclear whether patient
lab test
recent white paper juvenil diabet research foundat jdrf estim patient pre-symptomat
align prvb estim therefor estim initi address popul conserv like
grow time screen campaign driven prvb patient advocaci group
jdrf report estim delay onset two
year could annual per patient econom impact
children/adolesc adult factor cost
glucos monitor insulin use poor health outcom
recent estim direct medic cost singl case
diabet ketoacidosi dka hospit
mani undiagnos patient first present rang
given current option delay progress
pre-symptomat clinic stage think prevent
therapi delay measur year carri
signific price power limit payer pushback
compani report compani file jdrf jdrf fund health advanc white paper januari herold et al nejm desai et al diabet
debat investor
design aspect phase protect trial newli diagnos type diabet patient provid
confid failur prior protg trial repeat
major patient protg follow two year assess c-peptid level author note c-peptid
auc wide use endpoint trial accept fda primari endpoint phase protect trial
implement enrol cutoff c-peptid pmol/ml ensur patient minimum quantiti beta cell preserv
post-hoc subgroup analysi show c-peptid significantli preserv among treat teplizumab patient
diagnos week age year old one two year c-peptid also significantli preserv patient
start year miss one year patient appear caus inclus indian patient suggest result may
skew sever case geographi screen
primari endpoint use protg composit insulin units/kg/day year previous unvalid
sensit around cutoff point never assess slightli modifi cutoff insulin units/kg/day
studi would met statist signific one year even earli three month
protg subgroup analysi c-peptid level year
type auc area curv fda food drug administr hemoglobin
debat investor
avenu valu creation beyond type diabet credit given
remaind pipelin outsid teplizumab
teplizumab ascrib major valuat teplizumab inclus at-risk newli diagnos potenti
immunomodulatori mechan translat autoimmun diseas would set teplizumab pipelin
product could provid addit upsid beyond market opportun estim
addit therapeut area interest prvb includ inflammatori bowel diseas crohn diseas celiac diseas autoimmun
hepat psoriat arthriti rheumatoid arthriti
tiziana life scienc tlsa develop fulli human monoclon antibodi foralumab progress multipl sclerosi crohn
diseas non-alcohol steatohepat nash potenti graft-v -host diseas gvhd suggest avenu teplizumab
precursor molecul teplizumab evalu transplant reject clintrial indic one past non-diabet trial run
psoriasi stop inject site reaction therefor prvb larg free pursu indic interest
due clinic heterogen variabl background therapi lupu challeng indic develop
drug past two decad yield singl new approv agent gsk benlysta thought modest efficaci
remain earli day conserv assign modest contribut valuat
xncr obexelimab compar bispecif molecul phase lupu studi obexelimab miss primari
endpoint loss improv loi day efficacy-evalu patient howev met secondari endpoint time loi
 dart structur wherea obexelimab diabodi structur
addit disulfid bond structur compar obexelimab could confer greater stabil sustain efficaci
licens arrang celiac diseas provid singl digit royalti world-wide net sale
prvb current risk adjust royalti stream contribut meaning econom prvb
evalu celiac diseas non-respons gluten-fre diet month refractori celiac diseas type ii
progress small bowel lymphoma popul clear unmet need
think addit upsid deriv celiac patient respons gluten-fre diet seek addit prophylaxi
accident gluten exposur howev remain seen payer react valu proposit
type diabet nash non-alcohol steatohepat gvhd graft-v -host diseas ortho kung loi loss improv dart dual affin re-target tlsa tiziana life scienc
valuat market opportun
provent prvb initi coverag outperform
arriv price target prvb base risk-adjust discount cash flow dcf model assum
weight averag cost capit wacc termin growth rate share outstand million
valu prvb teplizumab at-risk newli diagnos type diabet lupu
present includ prevent preclin stage enter phase studi crohn diseas
mix phase data valuat asset repres upsid current estim
dcf discount cash flow wacc weight averag cost capit type diabet
assum market entri teplizumab at-risk estim peak sale million appli
risk discount arriv risk-adjust peak sale million
assum market entri teplizumab newli diagnos estim peak sale million
appli risk discount arriv risk-adjust peak sale million
assum eu market entri teplizumab at-risk newli diagnos estim eu peak sale
million at-risk million newli diagnos record as-yet-unidentifi partner
assum partner pay tier royalti prvb reach eu net sale aggreg highest tier model
estim eu peak royalti incom million appli risk discount blend at-risk newli
diagnos arriv risk-adjust peak royalti incom million
assum market entri estim peak sale million appli risk discount
arriv risk-adjust peak sale million
present model ex-u revenu ex-u commerci repres upsid current estim
assum market entri estim peak sale million appli risk discount
arriv risk-adjust peak sale million
assum eu market entri estim eu peak sale million appli risk discount
arriv risk-adjust peak sale million
world-wide ww peak sale million record prvb partner assum pay tier
royalti prvb reach ww net sale highest tier model estim ww peak royalti incom million
appli risk discount arriv risk-adjust peak royalti incom million
 market entri teplizumab at-risk
 peak sale
million risk-adjust discount
 market entri teplizumab newli
diagnos peak sale
million risk-adjust
eu market entri teplizumab at-risk
newli diagnos eu
aggreg peak royalti million
risk-adjust discount
 at-risk newli diagnos
 market entri lupu
 peak sale million
risk-adjust discount
 eu market entri
celiac diseas ww
aggreg peak royalti million
risk-adjust discount
fda ema accept file bla
teplizumab at-risk ye
earli reduc risk adjust
teplizumab at-risk discount
fda ema refus file bla
teplizumab at-risk ye
teplizumab at-risk one year
phase portion prevail trial lupu
risk-adjust lupu
phase portion prevail trial lupu
valuat adjust
celiac
reduc risk-adjust
celiac diseas discount
celiac
remov valuat
file earli success
clinic trial prv-
reduc
risk adjust
refus teplizumab regulatori file
 earli failur clinic
trial
model adjust individu note
failur on-going clinic trial teplizumab newli diagnos lupu and/or celiac
diseas may impact estim target price and/or rate expect teplizumab newli diagnos remain
model appropri discount rate top-line readout protect trial potenti limit downsid risk
next month lupu celiac diseas repres modest contribut valuat impli less downsid
clinic trial failur indic
fda ema and/or ex-u regulatori agenc may delay and/or deni approv teplizumab at-risk and/or newli
diagnos lupu and/or celiac diseas expect fda accept bla submiss
teplizumab roll basi delay submiss and/or request fda addit inform clinic non-
clinic and/or modul may push back expect launch date similarli delay ema interact may push
back expect eu launch date
loss first-mover/competit advantag and/or commercial/govern reimburs teplizumab at-risk and/or newli
diagnos type diabet lupu and/or celiac diseas may impact estim target price and/or
rate expect prvb seek commerci asset approv hiring/deploy salesforc except
partner intend seek partnership anoth compani
competitor product approv market prior prvb and/or competitor superior
therapeut profil prvb asset could advers impact futur competitor teplizumab could includ vaccin
one prvb develop lupu compet gsk benlysta lly/inci olumi
immunosuppress hydroxychloroquin rituximab celiac diseas compet sever
depend cash flow statu prvb probabl success develop teplizumab at-risk and/or newli
diagnos lupu and/or celiac diseas return right compani may need
rais addit fund financ sg activ come year model next equiti rais late fy
type diabet fda food drug administr ema european medicin agenc chemistri manufactur control gsk glaxosmithklin
innt innov biopharmaceut nsaid non-steroid anti-inflammatori drug research develop sg sale gener administr
revenu risk-adjust discount
tier royalti net revenu partner as-yet-unidentifi prvb
royalti risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
at-risk type diabet popul age y-o-i growth popul popul year old patient risk type diabet popul year patient risk type diabet diagnos direct rel patient risk type patient treat market growth annual price/rx price annual revenu at-risk diabet popul growth type diabet popul age y-o-i growth adult popul popul year old eu patient risk type diabet eu popul year patient risk type diabet diagnos direct rel patient risk type patient treat market growth annual revenu at-risk diabet popul eu growth
revenu risk-adjust discount
tier royalti net revenu partner as-yet-unidentifi prvb
royalti risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
newli diagnos type diabet popul age y-o-i growth popul popul year old newli diagnos patient type diabet yo newli diagnos type diabet patient newli diagnos patient risk type patient target market growth annual price/rx price annual revenu newli diagnos diabet popul growth diagnos type diabet popul age y-o-i growth adult popul popul year old eu newli diagnos patient type diabet eu yo newli diagnos type diabet patient newli diagnos patient risk type patient treat market growth annual revenu newli diagnos diabet popul eu growth
revenu risk-adjust discount
includ current valuat
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
lupu popul age y-o-i growth adult popul popul adult year old adult patient system lupu erythematosu sle popul adult year adult patient moderate-to-sever system lupu erythematosu sle adult patient system lupu adult patient moderate-to-sever sle fail treatment adult patient moderate-to-sever system lupu adult patient treat market y-o-i annual price/rx price annual revenu lupu growth
us
tier royalti net revenu prvb
royalti risk-adjust discount
model revenues/royalti non-risk-adjust appli indic risk discount arriv risk-adjust revenues/royalti
celiac diseas popul age y-o-i growth adult popul popul adult year old adult patient celiac diseas popul adult year adult patient refractory/non-respons celiac diseas includ type ii adult patient celiac adult patient treat market growth annual price/rx price annual revenu refractory/nonrespons celiac diseas growth diseas popul age y-o-i growth adult popul popul adult year old eu adult patient celiac diseas eu popul adult year adult patient refractory/nonrespons celiac diseas includ type ii adult patient celiac adult patient treat market growth annual revenu refractory/nonrespons celiac diseas eu growth
provent prvb initi coverag outperform
submiss bla/maa teplizumab at-risk fda/ema
interim data portion trial /-teplizumab newli
diagnos collabor precigen/actobio
top-line data protect trial newli diagnos
top-line data portion prevail trial lupu
start enrol proactiv trial celiac diseas trial collabor
top-line data proactiv trial celiac diseas trial collabor
file ind initi trial coxsacki viru vaccin healthi subject
top-line data trial newli diagnos
top-line data trial pre-symptomat
top-line data cohort trial establish five year minimum
top-line data trial establish five year minimum
top-line data bliss-believ combin trial lupu
top-line data brave ii trial lupu
top-line data trial celiac diseas gluten challeng
top-line data trial non-respons celiac diseas gluten-fre diet
top-line readout trial non-respons celiac diseas gluten-fre diet
type diabet sle system lupu erythematosu bla biolog licens applic market author applic complet respons letter fda food drug
provent prvb initi coverag outperform
teplizumab histori molecul
teplizumab stage comeback prvb pivot trial failur mgnx/lli underestim drug
potenti earliest stage type diabet
origin modifi version
precursor molecul agonist murin monoclon antibodi first develop jefferey blueston lab
ucsf conjunct late
potent immunosuppress approv fda reduc acut reject transplant organ plagu side
effect cytokin releas syndrom develop anti-murin antibodi human host
blueston team mutat fc region disabl fcr bind minim crosslink complex trigger
human molecul reduc immunogen
earli trial modifi name teplizumab competitor molecul european academ center otelixizumab
demonstr preserv c-peptid insulin by-product durabl year reason toler
disappoint era mgnx/lli
acquir right teplizumab partner develop
teplizumab advanc protg trial enrol newli diagnos patient evalu composit primari
endpoint percentag patient reduct insulin use u/kg/day one year
protg trial fail meet primari endpoint lead cancel develop molecul
privat compani tolerx acquir right competitor otelixizumab partner develop gsk
due concern ebv reactiv mononucleosi tolerx/gsk drop cumul dose otelixizumab
academ industry-sponsor trial otelixizumab subsequ fail c-peptid marker control
prvb acquir right continu develop
prvb acquir right teplizumab may launch ipo juli
prvb note protg design flaw like handicap odd success ex-u /eu patient advanc diseas minimum
c-peptid level requir enrol unvalid endpoint fda think shift c-peptid
post-hoc analysi suggest better c-peptid preserv patient younger patient recent diagnosi
post-protg failur prvb acquir right investigator-sponsor trial evalu teplizumab at-risk patient prior
diagnosi treatment delay onset clinic two year averag
compani report compani file compani press releas evaluatepharma fiercebiotech dolgin et al natur biotechnol ogi herold et al nejm kuhn weiner
hemoglobin ebv epstein-barr viru ipo initi public offer ucsf univers california san francisco
teplizumab mechan action type diabet
teplizumab prevent activ self-react t-cell improv ratio treg teff restor self-toler
preserv insulin-produc cell pancrea
teplizumab bind receptor cell
without cross-link complex
deriv
mutat fc region avoid fcr bind
bind
lead antigen modul
teplizumab complex
blind cell toward cognat antigen caus
render self-react cell anerg
ratio
increas number anerg exhaust
cell could reliabl marker respons
mediat tgf- product respons apoptosi
turn tgf- promot regulatori cell
inhibit effector cell skew antigen
similar mechan action modul
cell popul also observ clinic
trial anoth mab gsk otelixizumab
patient
clinicaltri gov entri
perdigoto et al diabetologia kuhn weiner et al immunotherapi herold et al diabet lebastchi et al diabet keymeulen et al nejm
autoantibodi present earliest pre-symptomat stage increas number highli predict
type
attack addit comment
epsilon
glutam acid decarboxylas synthes
inhibitori neurotransmitt gaba also found
autoimmun diseas
protein associ insulin-releas cell
appear later diseas process also found
autoimmun diseas
earliest stage pre-symptomat requir presenc two autoantibodi
stage classif requir two autoantibodi follow class insulin and/or
patient one autoantibodi low risk develop compar autoantibodi
titer predictor develop abnorm glucos metabol stage intermedi step autoantibodi
detect emerg clinic symptom
risk develop dysglycemia vs subject low vs high titer respect
appear second third autoantibodi markedli increas risk progress clinic stage
incid rate within year seroconvers one two three autoantibodi respect
screen autoantibodi asymptomat patient provid clinic benefit hint import
intercept diseas earliest phase
teddi observ studi newborn babi screen high-risk genotyp hla-dr/dq
intens follow-up shown episod diabet ketoacidosi dka hospit significantli reduc children
particip studi presum due increas vigil symptom
shield et al diabet xu krischer et al diabet insel et al diabet hagopian et al pediatr diabet
teplizumab find at-risk studi
singl cours treatment delay onset clinic high-risk particip two year averag
view signific game-chang pediatr endocrinologist
although prvb acquir teplizumab at-risk studi fund conduct consortium independ academ
institut includ trialnet nih jdrf
particip enrol high risk develop clinic diseas year old rel patient
abnorm glucos toler autoantibodi
subject receiv cours teplizumab placebo iv infus follow progress clinic
primari endpoint time develop random singl cours teplizumab iv infus
median time onset month receiv teplizumab vs month receiv placebo
month year receiv teplizumab free compar receiv placebo one subject
follow month year remain free
annual rate per year receiv teplizumab vs per year receiv placebo
type diabet macrogen nih nation institut jdrf juvenil diabet research foundat
teplizumab safeti profil at-risk studi
transient decreas white cell count common advers event associ teplizumab resolv within
day almost patient without increas risk infect
total grade event teplizumab-tr patient involv lymphopenia first day treatment
lymphopenia resolv day patient except one last day
rate infect similar teplizumab- placebo-tr group
spontan resolv rash occur teplizumab-tr patient
transient increas ebv cmv dna level associ viru reactiv teplizumab-tr patient one patient
teplizumab group symptom pharyng rhinorrhea cough day
teplizumab regulatory/commerci strategi at-risk
clear path timelin submiss regulatori file teplizumab at-risk eu
follow fda type meet ye plan complet roll bla submiss
expect submit clinic non-clin modul
expect need conduct addit clinic trial at-risk popul prior file bla
histor data set support bla file at-risk indic efficaci data set patient protg includ subgroup
analys studi abat delay
fda comfort patient safeti databas would like see specif analysi c-peptid level teplizumab group
chemistri manufactur control
expect submit modul critic path manufactur compar batch demonstr compar
mgnx/lli prvb drug product produc contract manufactur
manufactur process transfer agc
complet engin run decemb undertak gmp run analyt data two run first
submit fda part compar data packag elicit fda feedback
undertak three process perform qualif batch complet modul
timelin approv
 fda assum ye file prioriti review month potenti approv
eu ema meet target potenti approv
 commerci plan at-risk indic diseas awar hcp kol engag patient advocaci group partnership
requir screen initi sinc autoantibodi routin screen practic
launch focu famili direct rel patient autoantibodi dysglycemia estimate patient
fda food drug administr ema european medicin agenc bla biolog licens applic chemistri manufactur control macrogen
teplizumab phase protect studi newli diagnos
prvb conduct protect studi expand address market at-risk pre-diagnosi newli diagnos
patient captur critic window opportun
patient random teplizumab vs placebo
drug-treat group receiv two cours teplizumab
stimul c-peptid pmol/ml mix meal
clinic site eu
expect complet enrol
top-line readout
file newli diagnos indic
auc c-peptid mmtt week month
detect differ c-peptid treatment arm
time glycem target rang
mmtt mix meal toler test auc area curv
teplizumab c-peptid level cell function progress
c-peptid directli reflect capabl cell secret insulin make imper catch patient declin level
reach point-of-no-return
c-peptid valid method assess pancreat
younger patient show faster loss c-peptid better drug
respons protg teplizumab tidal alefacept studi
proinsulin cleav secret insulin c-peptid
pancreat beta cell insulin c-peptid produc
equal amount
level nm correspond preserv beta cell
sustain c-peptid level nm lead better
glycem control less diabet complic
three-stag model landmark studi dcct indic
dramat declin stimul peak c-peptid level
occur around time diagnosi
patient newli diagnos still residu cell
function provid narrow window opportun
crucial catch patient soon diagnosi
preserv mani beta cell possibl
translat clinic meaning outcom
treat patient clinic trial set immedi
diagnosi ideal sinc statist signific
easier demonstr expect steep declin c-
peptid placebo arm
narla palmer intern medicin review rigbi et al sherri et al lancet
dcct diabet control complic trial cgm continu glucos monitor
teplizumab c-peptid level predictor respons
subgroup analysi at-risk studi indic c-peptid level use biomark identifi patient
respons treatment teplizumab
declin c-peptid level predict greater benefit teplizumab delay progress
subgroup analysi found significantli better respons patient c-peptid lower median nm enrol
lower c-peptid impli patient less remain beta cell mass closer clinic threshold diagnos
treat patient nm c-peptid result dramat reduc progress clinic within month continu
protect year receiv teplizumab free vs receiv placebo
treat patient lower c-peptid level logic strategi intercept acceler diseas cours
shortli progress clinic focu prvb on-going phase protect studi
effect teplizumab treatment particip whose c-peptid area curv oral glucos toler test random
 median nm
teplizumab efficaci c-peptid prior clinic studi
teplizumab consist demonstr benefit preserv c-peptid level even though past trial vari design
baselin demograph impli outcom could improv select ideal popul
number subject
differ c-peptid
hoc analysi protg subgroup identifi characterist better
respond provid guidanc select target popul
list factor interest differ c-peptid vs placebo
ideal popul phase protect studi teplizumab enrol
patient age diagnos within past week c-peptid
nm similar protg subgroup may lead better respons
although characterist respond protg studi deriv post-hoc analysi similar trend also
observ trial teplizumab otelixizumab
abat teplizumab insulin use studi entri
significantli lower respond u/kg/day vs non-
beta cell mass respond
ttedd otelixizumab subject c-peptid percentil
studi entri significantli higher preserv c-peptid
phase studi teplizumab enrol patient week
diagnosi although baselin factor c-peptid insulin use
less favor abat protg trial
achiev best result date signific improv
c-peptid level insulin use seen protg patient
week diagnosi also greatest improv outcom
efficaci year
time diagnos
teplizumab regulatory/commerci strategi newli diagnos
manag adher fda/ema guidanc preserv beta cell function patient protect studi
set potenti label expans
protect studi expect complet enrol top-line data
fda guidanc accept chang c-peptid auc follow mix meal toler test primari endpoint one year recommend
analyz c-peptid level one two year assess exogen insulin usag secondari endpoint
ema guidanc accept chang c-peptid one follow frequenc hypoglycem episod percentag patient
requir insulin therapi relev reduct insulin co-primari endpoint includ co-primari endpoint one latter
option key secondari endpoint ema prefer see sustain benefit two year
newli diagnos patient age year old target launch
manag plan pursu eu commerci partner at-risk newli diagnos indic
goal expand address
screen campaign addit
age group
annual mainten dose
patient like strategi
combo approach could develop
exist therapi
could pursu
compani report compani file compani press releas fda guidanc industri diabet mellitu ema guidanc clinic investig diabet mellitu
type diabet fda food drug administr ema european medicin agenc eu european union auc area curv
teplizumab competitor
knowledg prvb far ahead develop at-risk newli diagnos vs competitor
regen medicin approach consist transform allogen stem cell
insulin-produc cell follow transplant patient
septemb vertex acquir privat
cash basi preclin program induc pluripot
stem cell becom small nest cell pancreat islet
howev stem cell-deriv islet must transplant within encapsul
devic protect autoimmun attack patient immun
system altern patient receiv convent immunosuppress
viacyt sernova cell pouch two
compani purs develop encapsul islet reach
studi product
earli data viacyt studi look mix
variabl consist durat engraft
technolog potenti cur hurdl includ invas
procedur high cost unknown durabl effect
natur islet deriv pancrea organ donor
jnj subsidiari janssen run early-stag trial simponi golimumab at-risk/pre-symptomat newli
diagnos readout expect
simponi anti-tumor necrosi factor tnf monoclon antibodi current approv moderate-to-sever rheumatoid arthriti psoriat
arthriti ankylos spondyl moderate-to-sever ulcer coliti
simponi evalu studi similar enrol criteria teplizumab at-risk studi also
studi similar enrol criteria teplizumab newli diagnos studi protect
trialnet/jdrf run early-stag investigator-sponsor trial prevent wide rang immunomodul
agent includ hydroxychloroquin anti-thymocyt globulin orencia abatacept rituxan rituximab
although composit matter patent expir teplizumab eu regulatori approv would provid
year statutori market exclus new biolog
potenti role viral infect
enterovirus coxsackieviru cvb thought trigger autoimmun respons target destroy insulin-
produc cell pancrea
accumul evid anim human studi epidemiolog ecolog case report case-control prospect
cohort autopsi point toward follow
common antigen structur share viral cell protein suggest immun cross-react could caus
mechanist studi anim also show direct infect cell enterovirus damag
presenc cvb type enteroviru associ larg prospect birth-cohort studi
enterovirus detect pancreat biopsi newli diagnos patient
propos model enterovirus-induc cell damag
immun cross-react lead
develop progress
vaccin cvb prevent
dunn et al diabetologia hyti et al expert review vaccin sioofy-khojin et al diabetologia laitinen et al diabet oikarinen et al diabet
primari prevent
phase first-in-human studi expect initi deliv first data manag
envis vaccin at-risk patient follow eventu univers vaccin possibl
object evalu safeti
immunogen healthi volunt
toler
dose level sentinel group
academ studi eudract norway sweden denmark
object evalu efficaci antivir treatment regimen progress residu insulin secret
outcom chang c-peptid follow mix meal toler test month primari insulin dose number sever
hypoglycem event presenc enteroviru
enrol children/adolesc age year old within three week diagnosi
antivir treatment pleconaril ribavirin match placebo
readout expect trial success impli antivir could competitor teplizumab newli diagnos howev
antivir expect effect primari prevent compar vaccin
histori molecul
develop bispecif molecul inhibit cell use mgnx proprietari platform licens
prvb tandem teplizumab
origin first partner tak
origin develop molecul use dual-
affin re-target dart platform produc sever
drug candid pipelin
enter collabor tak provid tak
option obtain exclus world-wide licens
follow deliveri data packag includ pre-defin studi
interim data studi present eular
show clean safeti dose-depend on-target activ inhibit
 cell receptor signal without deplet cell
prior final data studi tak opt end
collabor right revert tak state
decis base re-priorit clinic program
prvb continu develop lupu
report final data studi eular
confirm safeti healthi volunt present addit data
support mechan action
given mgnx focu immuno-oncolog manag sought new
partner develop autoimmun indic
concurr out-licens
teplizumab prvb may
also enter collabor prvb
refer
prvb continu develop multipl
ascend dose studi safeti data healthi subject
portion expect
portion enrol lupu patient demonstr clinic proof-
bispecif molecul design use number differ
structur case typic antibody-lik structur
preserv wherea other mgnx dart molecul
optim variabl region and/or dispens fc region
exampl dart develop includ flotetuzumab
compani report compani file kontermann brinkmann drug discoveri today
mechan action system lupu erythematosu
system lupu erythematosu sle classic autoimmun diseas driven autoreact cell autoantibodi
product provid ideal test case mechan
human bispecif scaffold molecul target
fcriib cell co-receptor
trigger inhibit cell function suppress autoantibodi product
downregul express
boost neg feedback loop regul cell without cell platelet deplet
cumul effect prevent activ class-switch nave cell
 cell mediat lupu secret autoantibodi present autoantigen
cell
antinuclear antibodi ana characterist sle autoantibodi detect
virtual patient
current treatment rituximab epratuzumab abatacept work target
cell cell-medi activ cell
co-engag could viabl approach lupu
known inhibitori fcr immun system regul
immun toler autoimmun
express downregul sle patient
singl nucleotid polymorph human fcriib gene result receptor
dysfunct associ sle
theoret concern fundament biolog
off-target engag dendrit cell could lead undesir matur
differenti express could present sle patient
drug could rapidli consum intern bind
block could potenti toxic cell progenitor
compani report compani file verbeek et al frontier immunolog kaul et al natur review diseas primer vaughan et al blood
summari preclin clinic data
demonstr target engag inhibit cell activ without deplet cell count
target efficaci glp safeti
simultan bind receptor
cell co-
receptor cell
trigger activ cell
translat inhibit cell
prolifer ig secret
toxicolog studi yield noael
highest dose mg/kg
downregul cell surfac bcr
igd igg co-
observ without deplet cell
 cell respons hav vaccin
term hav-igg product
safeti subject
develop teae grade
higher advers event deem
relat studi drug
bcr cell receptor glp good laboratori practic noael observ advers effect level bcr cell receptor hav hepat viru igg immunoglobulin teae treatment-emerg
phase prevail studi sle
safeti data healthi volunt expect follow enrol lupu patient
demonstr efficaci clinic endpoint week
studi adult healthi volunt
top-line result
develop pathway prevent
gene therapi product
proof-of-concept studi expans
cohort lupu patient
possibl recent diagnos lupu
patient may enrol keep
prvb theme intercept
prevent
polymorph heavili
associ lupu
manag use
protein creatinin ratio daili
blood biomark measur
xncr obexelimab competitor similar moa
mechan action de-risk xncr obexelimab show moder effect sle
could outperform given latter higher stabil
obexelimab revers cell inhibitor
obexelimab revers cell inhibitor diabodi structur
fv domain fc domain
enhanc affin
affin kd nm compar
howev diabodi structur gener
less stabl dart
contain addit disulfid bond
miss studi obexelimab sle albeit posit trend
enrol patient moderate-to-sever non-organ threaten
proport patient loss
improv day met obexelimab vs
placebo
time flare significantli longer obexelimab-tr group
sustain llda low diseas month
sae observ obexelimab patient sae placebo
patient opportunist infect death report infect
rate low compar sle trial
merril et al annal rheumat diseas et al molecular immunolog
moa mechan action sle system lupu erythematosu llda lupu low diseas activ state sae seriou advers event
histori molecul
chang hand multipl time current amgn-prvb collabor zero celiac diseas
promis indic develop
origin therapi rheumatoid arthriti psoriasi
gmab origin develop molecul monoclon antibodi target licens
reformul drug began test rheumatoid arthriti
top-line result rheumatoid arthriti demonstr symptom improv patient
view competit evolv therapeut landscap ra
pivot psoriasi proof-of-concept result neg ultim shelv molecul
celimmun shift focu celiac diseas
licens celimmun privat biotech compani found prvb member francisco leon ashleigh
palmer develop celiac diseas
grow bodi evid support role block celiac diseas inhibit destroy intestin mucosa
prevent regulatori cell downregul suppress gluten peptid present apc
part term deal option re-acquir two proof-of-concept studi celiac diseas
proof-of-concept studi report signal efficaci relev popul celiac diseas post-gluten challeng refractori
right revert upon acquisit celimmun
prvb continu develop celiac diseas
licens prvb next round clinic develop given prvb manag familiar
molecul sinc day celimmun
prvb conduct financ dose-find trial prvb design celiac patient non-
respons gluten-fre diet expect start enrol
upon complet trial expect prvb elig mileston payment potenti
elect advanc trial commerci prvb would receiv single-digit royalti
choos continu develop pay mileston right transfer prvb
proof-of-concept studi celiac diseas
phase data valid mechan action suggest symptomat improv despit
mix result mucos histolog
phase studi non-respons celiac diseas
gluten-fre diet significantli reduc iel count
improv symptom ced-pro high-dos gluten
challeng g/d wk though fail improv vh cd
phase studi refractori celiac diseas type ii
significantli reduc diarrhea bsf score show
trend improv aberr iel count vh cd
though limit short follow-up small sampl
phase proactiv studi celiac diseas
top-line data proactiv studi report guid dose select pivot trial
like incorpor symptom histolog approv endpoint
dose-find proactiv studi expect
begin enrol
enrol adult celiac patient respond
gluten-fre diet symptom histolog damag
patient random three dose level
placebo treatment durat six month via
subcutan inject everi week
primari endpoint valid ced-pro gi symptom
iel count histolog safeti
manag believ appropri
substanti number celiac patient
even patient strictli adher gluten-fre diet
experi cross-contamin cereal flour
small amount gluten mg potenti lead
immun reaction mucos damag
manag estim celiac patient could
inadvert expos gluten debilit symptom
given point time
fda would look symptom improv worsen
histolog approv endpoint
histolog vh cd continu measur mucos
inflamm thought sensit measur
chang
marsh-
categor measur
modifi marsh classif oberhub histolog celiac diseas
vh cd consid normal
equival marsh consist diagnosi celiac diseas
provent prvb initi coverag outperform
provent inc incom statement valu mm except ep averag type system lupu celiac expens oper expens product royalti oper loss incom expens interest fair valu warrant incom expens profit loss incom tax expens incom seri convert redeemablepref incom loss per share attribut common averag share outstand averag share outstand
provent inc balanc sheet valu mm except ep averag assetscash cash expens current current asset properti equip long-term stockhold equiti liabil current liabil account research develop accru profession current liabil warrant total equiti stockhold deficit addit total stockhold equiti liabil stockhold equiti
provent inc statement valu mm except ep averag flow oper activ net reconcil net loss net cash use oper compens consider connect acquisit product fair valu warrant oper asset liabil prepaid expens current cash use oper flow invest activ purchas properti market market cash use invest flow financ activ proce underwritten public offer privat placement initi public offer exercis stock financ cost relat initi public issuanc seri convert redeem prefer stock issuanc common cash provid financ increas cash cash cash equival begin cash equival end
provent inc discount analysi valu tax stock compens capit chang work free cash
provent prvb initi coverag outperform
autoimmun diseas result loss abil produc insulin regul glucos metabol
requir life-long insulin replac carri signific health burden
pathogenesi diseas
autoimmun diseas caus insulin defici
patient requir life-long use exogen insulin face
loss insulin-produc cell pancrea
daili insulin inject routin glucos monitor high
burden qualiti life
glycem control per ada guidelin alway
achiev expos patient microvascular macrovascular
patient
risk
life-threaten event diabet
ketoacidosi dka hypoglycemia
life expect patient onset younger age
year shorter averag compar non-diabet age-
prevent aim intercept earlier phase
preserv remain cell delay progress clinic
underli caus diseas chronic autoimmun
reaction pancreat cell islet
autoantibodi pancreat present newli
diagnos patient pre-symptomat subject
develop diseas
progress stage presenc
autoantibodi blood glucos level symptom
autoimmun find present year diagnosi
made clinic onset becom appar
cell increasingli lost diseas progress
cell rate
type
type
type
slow fast
slow
sle autoantibody-medi diseas wide rang clinic present efficaci observ belimumab
rituximab valid target cell therapeut approach
pathogenesi diseas
sle caus innat adapt immun system direct inappropri
respons nucleic acid-contain cellular particl
 cell produc autoantibodi form immun complex result
major clinic manifest
goal therapi ensur long-term surviv achiev lowest possibl diseas
activ prevent organ damag improv qualiti life
moder diseas hydroxychloroquin chloroquin short-term steroid long-term
azathioprin methotrex
 cellcept azathioprin cyclophosphamid rituximab
despit avail option patient physician unsatisfi therapeut
moderate-to-sever patient experienc diseas flare last month
sever patient deriv less benefit steroid therapi base recent survey
newer biolog elimin inhibit activ autoreact cell
roch rituximab improv diseas activ spare steroid
improv ana level complet remiss rate relaps rate
rituximab mechan indic cell deplet viabl approach sle
deplet long-liv plasma cell tissu potenti provid better outcom
gsk belimumab benlysta bli inhibitor approv sle despit
margin benefit standard-of-car therapi
combin regimen belimumab rituximab undergo evalu
bliss-believ trial expect read june
ced driven cell aberrantli react gluten peptid mount autoimmun attack line
small intestin gluten-fre diet effect patient strict avoid challeng
pathogenesi diseas
genet suscept individu gliadin fraction gluten protein found wheat cereal grain trigger autoimmun
respons gluten-sensit cell small intestin
autoimmun respons involv anti-gluten cell antibodi autoantibodi
tissu transglutaminas
activation/expans intraepitheli lymphocyt compos mainli cytotox cell
integr small
intestin epithelium lost damag visual mucos villou atrophi biopsi aid
diagnosi gluten-specif memori cell persist blood rapidli re-expand oral gluten challeng
persist symptom recurr villou atrophi
malabsorpt despit adher strict gluten-fre
diet month rare
refractori ced
character
clonal tcr gene rearrang associ
potenti role manag ced
therapi formal approv ced
although strict gluten-fre diet effect
patient difficult adher practic
could provid protect unintend
gluten exposur ced patient well address
rare non-responsive/refractori popul
mechan drive activ malign transform intraepitheli
lymphocyt celiac diseas type ii refractori celiac diseas
crohn diseas
high placebo respons rate derail phase studi crohn diseas put asset
backburn janssen pass develop
mechan action
oral small-molecul inhibitor
inhibit pro-inflammatori macrophag dendrit cell
reduc product tnf- mediat
phase princ proof-of-concept studi crohn diseas
enrol patient moderate-to-sever crohn diseas
divid two group biolog therapy-nav
result provid addit proof-of-mechan
function inhibit
inhibit migrat inflammatori cell gut
improv chang cdai
observ monotherapi due higher-than-
expect placebo effect possibl relat use background
prvb janssen enter licens agreement
grant prvb exclus global right purpos develop
commerci ibd includ crohn
princ studi janssen longer intend take
option buy back right compound
prvb free sub-licens program world-wide basi
ibd manag
indic would move forward without partner
develop
ulcer coliti
studi fail show signal efficaci ulcer coliti termin develop asset
low odd resurrect
mechan action
phase puls studi ulcer coliti
target extracellular domain surfac epitheli
cell block signal
inhibit cytokin releas modul innat
enrol patient moderate-to-sever ulcer coliti uc
divid two group biolog therapy-nav biolog
clean safeti target engag observ
improv clinic endoscop histolog
uc-rel efficaci endpoint observ
elev gene signatur previous observ uc
patient well puls therefor appear downstream
circumstanti effect contribut significantli
prvb enter licens agreement janssen
develop commerci includ conting
mileston payment janssen total
prvb intend continu develop uc
favor safeti profil could offer opportun
sub-licens asset evalu indic includ
sever influenza emerg viral diseas
compani mention report
price target dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
competit financ
price target dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
competit financ
price target dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
competit financ
price target dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
competit financ
price target dcf-base discount rate termin growth rate risk includ clinic regulatori commerci
competit financ
